

CITATION REPORT

List of articles citing

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery

DOI: 10.1016/j.schres.2003.09.011
Schizophrenia Research, 2004, 68, 283-97.

Source: <https://exaly.com/paper-pdf/37406144/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1099	A brief cognitive assessment for use with schizophrenia patients in community clinics. <i>Schizophrenia Research</i> , 2004 , 71, 273-83	3.6	54
1098	Identification of separable cognitive factors in schizophrenia. <i>Schizophrenia Research</i> , 2004 , 72, 29-39	3.6	947
1097	Treatment-refractory schizophrenia. 2005 , 18, 165-73		10
1096	Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. 2006 , 32, 474-85		129
1095	Developing therapeutics for schizophrenia and other psychotic disorders. 2005 , 2, 579-89		19
1094	Defining a cognitive function decrement in schizophrenia. 2005 , 57, 688-91		237
1093	Lateralized cognitive dysfunction and psychotic symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2005 , 80, 151-61	3.6	50
1092	Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. <i>Schizophrenia Research</i> , 2005 , 80, 1-8	3.6	72
1091	Cognition in schizophrenia: impairments, determinants, and functional importance. 2005 , 28, 613-33, 626		173
1090	Lamotrigine for schizophrenia. 2006 , CD005962		23
1089	Convergence of clinical staff ratings and research ratings to assess patients with schizophrenia in nursing homes. 2006 , 57, 838-43		7
1088	Effects of biasing the location of stimulus presentation, and the muscarinic cholinergic receptor antagonist scopolamine, on performance of a 5-choice serial reaction time attention task in rats. 2006 , 17, 71-85		18
1087	The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome. 2006 , 28, 260-9		106
1086	Baseline neurocognitive deficits in the CATIE schizophrenia trial. 2006 , 31, 2033-46		374
1085	The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. 2006 , 163, 426-32		277
1084	Clinicians' concepts of the cognitive deficits of schizophrenia. 2007 , 33, 648-51		9
1083	Psychomotor slowing in schizophrenia. 2007 , 33, 1038-53		163

1082	Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia. 2008 , 34, 494-506	20
1081	Less unique variance than meets the eye: overlap among traditional neuropsychological dimensions in schizophrenia. 2008 , 34, 423-34	37
1080	Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. 2007 , 164, 1061-71	210
1079	Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. 2008 , 34, 656-63	18
1078	Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. 2007 , 64, 532-42	647
1077	An exploratory study of the relationship between mother-infant interaction and maternal cognitive function in mothers with mental illness. 2007 , 25, 255-269	16
1076	Cognition as an outcome measure in schizophrenia. 2007 , 50, s46-51	63
1075	Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings. 2007 , 133, 833-58	400
1074	Psychopathological and neuropsychological correlates of source monitoring impairment in schizophrenia. 2007 , 150, 51-9	35
1073	Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients. 2007 , 22, 365-70	26
1072	P.3.a.025 Sleep and circadian activity/rest disturbances in schizophrenia patients in comparison to unemployed healthy controls. 2007 , 17, S415-S416	
1071	P.3.a.026 Age dependent discrepancies between computerized and paper cognitive tests in patient with schizophrenia. 2007 , 17, S416	
1070	P.3.c.078 Catechol-O-methyltransferase gene polymorphism in symptomatology of schizophrenia. 2007 , 17, S469-S470	
1069	P.3.c.079 Negative impact of total antipsychotic dosage on cognition as assessed by the Brief Assessment of Cognition in Schizophrenia (BACS). 2007 , 17, S470	
1068	P.3.c.080 Association between 759C/T and 897G/C polymorphisms of the 5HT2C receptor gene and olanzapine-induced weight gain. 2007 , 17, S470-S471	
1067	Pseudoneglect in schizophrenia: a line bisection study with cueing. 2007 , 12, 222-34	22
1066	Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS). 2007 , 1, 260-265	12
1065	Brief assessment of cognition in schizophrenia: validation of the Japanese version. 2007 , 61, 602-9	166

1064	Development and validation of a World-Wide-Web-based neurocognitive assessment battery: WebNeuro. 2007 , 39, 940-9		117
1063	Working memory in schizophrenia: an EEG study using power spectrum and coherence analysis to estimate cortical activation and network behavior. 2008 , 21, 128-37		56
1062	The Brief Assessment of Cognition in Schizophrenia. Normative data for the Italian population. 2008 , 29, 85-92		98
1061	Design paper: The CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis. 2008 , 9, 42		11
1060	Predictors of subjective and objective quality of life in outpatients with schizophrenia. 2008 , 62, 404-11		67
1059	Course of cognitive functioning during the stabilization phase of schizophrenia. 2008 , 42, 259-67		23
1058	Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia. <i>Schizophrenia Research</i> , 2008 , 99, 139-48	3.6	60
1057	General and social cognition in first episode schizophrenia: identification of separable factors and prediction of functional outcome using the IntegNeuro test battery. <i>Schizophrenia Research</i> , 2008 , 99, 182-91	3.6	85
1056	Comparative psychometric properties of the BACS and RBANS in patients with schizophrenia and schizoaffective disorder. <i>Schizophrenia Research</i> , 2008 , 105, 86-94	3.6	8
1055	Do people with schizophrenia who have objective cognitive impairment identify cognitive deficits on a self report measure?. <i>Schizophrenia Research</i> , 2008 , 105, 156-64	3.6	76
1054	Schizophrenia. 2008 , 85-108		1
1053	A NEW TOOL ASSESSING INTENTION READING, THE V-SIR, AS A MEASURE OF SEVERITY IN SCHIZOPHRENIA. <i>Schizophrenia Research</i> , 2008 , 102, 150	3.6	2
1052	SPANISH VALIDATION OF THE BACS (BRIEF ASSESSMENT IN COGNITION IN SCHIZOPHRENIA); PERFORMANCE IN PATIENTS AND HEALTHY CONTROLS. <i>Schizophrenia Research</i> , 2008 , 102, 150	3.6	
1051	Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). <i>Schizophrenia Research</i> , 2008 , 102, 108-15	3.6	207
1050	Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. 2008 , 23, 271-82		11
1049	[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. 2008 , 34, 557-62		10
1048	Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. 2008 , 30, 1565-89		54
1047	Insight into neurocognitive dysfunction in schizophrenia. 2008 , 34, 1221-30		117

1046	Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. 2008 , 33, 1217-28	116
1045	Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. 2008 , 42, 496-504	73
1044	Galantamine for the treatment of cognitive impairments in people with schizophrenia. 2008 , 165, 82-9	147
1043	Should cognitive impairment be included in the diagnostic criteria for schizophrenia?. 2008 , 7, 22-8	102
1042	Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. 2008 , 14, 209-21	35
1041	A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. 2008 , 28, 59-63	41
1040	Interpretation of the RBANS in inpatient psychiatry: clinical normative data and prevalence of low scores for patients with schizophrenia. 2009 , 16, 31-41	22
1039	Verbal working memory and functional outcome in patients with unipolar major depressive disorder. 2009 , 10, 591-4	4
1038	Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. 2009 , 166, 805-11	329
1037	Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. 2009 , 34, 1885-903	147
1036	The cognitive and affective structure of paranoid delusions: a transdiagnostic investigation of patients with schizophrenia spectrum disorders and depression. 2009 , 66, 236-47	218
1035	The self-assessment scale of cognitive complaints in schizophrenia: a validation study in Tunisian population. 2009 , 9, 66	8
1034	Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome. 2009 , 31, 462-71	52
1033	A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. 2009 , 34, 1322-9	125
1032	Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation. 2009 , 169, 191-6	74
1031	Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. <i>Schizophrenia Research</i> , 2009 , 107, 275-85 ^{3.6}	35
1030	'Theory' of mind impairment in patients affected by schizophrenia and in their parents. <i>Schizophrenia Research</i> , 2009 , 115, 278-85	3.6 52
1029	Motivational deficits as the central link to functioning in schizophrenia: a pilot study. <i>Schizophrenia Research</i> , 2009 , 115, 333-7	3.6 84

1028	Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. 2009 , 7, 28		28
1027	Verbal working memory impairment in patients with current episode of unipolar major depressive disorder and in remission. 2009 , 32, 346-7		17
1026	Prospective memory in Parkinson disease across laboratory and self-reported everyday performance. 2009 , 23, 347-58		60
1025	The comprehension of idiomatic expressions in schizophrenic patients. 2010 , 48, 1032-40		35
1024	Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. 2010 , 25, 116-25		45
1023	A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. 2010 , 9, 27		67
1022	Computer-aided neurocognitive remediation in schizophrenia: durability of rehabilitation outcomes in a follow-up study. 2010 , 20, 659-74		30
1021	Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders. 2010 , 11, 637-48		6
1020	A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries. 2010 , 32, 937-52		32
1019	Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. 2010 , 35, 2427-39		116
1018	Definition and Measurement of Neurocognition and Social Cognition. 2010 , 1-22		4
1017	Comparing the influences of age and disease on distortion in the clock drawing test in Japanese patients with schizophrenia. 2010 , 18, 908-16		3
1016	Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S). <i>Schizophrenia Research</i> , 2010 , 116, 243-51	3.6	40
1015	A comparison of insight into clinical symptoms versus insight into neuro-cognitive symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2010 , 118, 134-9	3.6	49
1014	Emotional experience predicts social adjustment independent of neurocognition and social cognition in schizophrenia. <i>Schizophrenia Research</i> , 2010 , 122, 156-63	3.6	31
1013	Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. 2010 , 24, 1037-44		107
1012	Investigation of clinical factors influencing cognitive function in Japanese schizophrenia. 2010 , 66, 340-4		21
1011	Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. 2010 , 34, 463-8		40

1010	The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia. 2010 , 178, 33-8		15
1009	The Letter-Number Sequencing Test and its association with potential to work among people with psychotic illness. 2010 , 25, 101-4		5
1008	Assessment of Therapy-Resistant Schizophrenia. 2010 , 9-32		2
1007	Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later. 2010 , 36, 869-79		175
1006	A digit symbol coding task as a screening instrument for cognitive impairment in first-episode psychosis. 2011 , 26, 48-58		38
1005	Vocational rehabilitation improves cognition and negative symptoms in schizophrenia. <i>Schizophrenia Research</i> , 2011 , 126, 265-9	3.6	30
1004	A path model investigation of neurocognition, theory of mind, social competence, negative symptoms and real-world functioning in schizophrenia. <i>Schizophrenia Research</i> , 2011 , 125, 152-60	3.6	161
1003	Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. <i>Schizophrenia Research</i> , 2011 , 125, 221-35	3.6	126
1002	Disconnected and underproductive speech in schizophrenia: unique relationships across multiple indicators of social functioning. <i>Schizophrenia Research</i> , 2011 , 131, 152-6	3.6	27
1001	Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: a comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP). <i>Schizophrenia Research</i> , 2011 , 130, 137-42	3.6	29
1000	Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. <i>Schizophrenia Research</i> , 2011 , 132, 24-7	3.6	107
999	Quality of life and cognitive dysfunction in people with schizophrenia. 2011 , 35, 53-9		41
998	Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia. 2011 , 188, 187-90		22
997	[What perspectives for cognitive remediation in schizophrenia?]. 2011 , 37 Suppl 2, S155-60		1
996	Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results. 2011 , 26, 74-7		19
995	Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls. 2011 , 26, 69-73		51
994	Quality of life and its predictors in people with schizophrenia. 2011 , 58, 167-74		34
993	Subjective and Objective Cognitive Dysfunction in Schizophrenia - is there a Link?. 2011 , 2, 148		28

992	Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia. 2011 , 6, e20469	29
991	The Singapore flagship programme in translational and clinical research in psychosis. 2011 , 5, 290-300	7
990	The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial. 2011 , 11, 203	8
989	Quantifying clinical relevance in the treatment of schizophrenia. 2011 , 33, B16-39	73
988	Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. 2011 , 11, 160	14
987	The importance of measuring psychosocial functioning in schizophrenia. 2011 , 10, 18	55
986	The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. 2011 , 35, 573-88	1184
985	Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?. 2011 , 10, 19-31	45
984	The heterogeneity of antipsychotic response in the treatment of schizophrenia. 2011 , 41, 1291-300	42
983	A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. 2011 , 37, 538-45	56
982	Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients. 2012 , 16, 138-42	17
981	Eye-contact perception in schizophrenia: relationship with symptoms and socioemotional functioning. 2012 , 121, 616-27	54
980	Psychotropic drug treatment, clinical characteristics and cognitive processing speed in patients with schizophrenia: results from the ELAN study. 2012 , 45, 138-45	8
979	Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. 2012 , 26, 806-12	26
978	A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. 2012 , 32, 593-601	25
977	A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. 2012 , 35, 165-73	28
976	Predictors of treatment utilisation at cognitive remediation groups for schizophrenia: the roles of neuropsychological, psychological and clinical variables. 2012 , 22, 516-31	12
975	Guide to Assessment Scales in Schizophrenia. 2012 ,	3

974	Antipsychotic agents: efficacy and safety in schizophrenia. 2012 , 4, 173-80		15
973	Do people with schizophrenia lack emotional intelligence?. 2012 , 2012, 495174		14
972	Brief screening for executive dysfunction in schizophrenia in a rehabilitation hospital. 2012 , 24, 215-22		8
971	Predictors of change in functional competence and functional behavior after functional adaptation skills training for schizophrenia. 2012 , 200, 705-11		14
970	Social cognition in 22q11.2 microdeletion syndrome: relevance to psychosis?. <i>Schizophrenia Research</i> , 2012 , 142, 99-107	3.6	57
969	Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study. <i>Schizophrenia Research</i> , 2012 , 142, 153-8	3.6	17
968	Clinical correlates associated with cognitive dysfunction in people with schizophrenia. 2012 , 66, 491-8		17
967	Predictors of quality of life in inpatients with schizophrenia. 2012 , 197, 199-205		27
966	Self-awareness of cognitive functioning in schizophrenia: patients and their relatives. 2012 , 198, 207-11		21
965	Theory of mind and emotion processing training for patients with schizophrenia: preliminary findings. 2012 , 198, 371-7		53
964	Patterns of evidence integration in schizophrenia and delusion. 2012 , 200, 108-14		19
963	Do Symptoms and Cognitive Problems Affect the Use and Efficacy of a Web-Based Decision Support System for Smokers With Serious Mental Illness?. 2012 , 8, 315-325		13
962	Assessing cognition in schizophrenia: a comparison of clinician and computerized test administration. 2012 , 19, 9-15		3
961	Self-assessment of psychological stress in schizophrenia: Preliminary evidence of reliability and validity. 2012 , 195, 39-44		16
960	The pilot study of a Neuropsychological Educational Approach to Cognitive Remediation for patients with schizophrenia in Japan. 2012 , 195, 107-10		12
959	Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. 2012 , 73, 842-53		200
958	Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic. 2012 , 36, 300-6		24
957	Neuropsychological and functional correlates of clock-drawing test in elderly institutionalized patients with schizophrenia. 2012 , 12, 242-7		3

956	Identifying attentional deficits in people with first-episode psychosis with the Scale for the Assessment of Negative Symptoms attention subscale: is it possible?. 2012 , 53, 701-5		5
955	A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. <i>Schizophrenia Research</i> , 2012 , 138, 35-8	3.6	24
954	Happiness in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2012 , 141, 98-103	3.6	36
953	Brain structural changes and neuropsychological impairments in male polydipsic schizophrenia. 2012 , 12, 210		10
952	Antipsychotics and Cognitive Functioning: A Critical Review. 2012 , 2, 37-46		0
951	The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date. 177-191		
950	The relationship between acoustic startle response measures and cognitive functions in Japanese patients with schizophrenia. 2012 , 14, 131-8		9
949	Functional outcomes in schizophrenia: understanding the competence-performance discrepancy. 2012 , 46, 205-11		38
948	9-OH risperidone response in risperidone poor responders: An open study of drug response concordance. 2012 , 18, 109-113		2
947	Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. 2013 , 13, 176		11
946	The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. 2013 , 13, 127		30
945	Psychosocial and neuropsychiatric predictors of subjective recovery from psychosis. 2013 , 208, 203-9		34
944	Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery: validation of the Japanese version. 2013 , 67, 182-8		26
943	P.1.C.002 Clinical and therapeutic correlates of neurological soft signs in first-episode psychosis. 2013 , 23, S181-S182		
942	Double-blind randomized controlled study showing symptomatic and cognitive superiority of bifrontal over bitemporal electrode placement during electroconvulsive therapy for schizophrenia. 2013 , 6, 210-7		39
941	Unraveling the relationship between obesity, schizophrenia and cognition. <i>Schizophrenia Research</i> , 2013 , 151, 107-12	3.6	27
940	Sequential processing deficits in schizophrenia: relationship to neuropsychology and genetics. <i>Schizophrenia Research</i> , 2013 , 151, 91-6	3.6	4
939	Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. 2013 , 13, 235		15

938	Association of the Hermansky-Pudlak syndrome type 4 (HPS4) gene variants with cognitive function in patients with schizophrenia and healthy subjects. 2013 , 13, 276		5
937	Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. 2013 , 47, 1843-8		21
936	Reduction of cortical GABAergic inhibition correlates with working memory impairment in recent onset schizophrenia. <i>Schizophrenia Research</i> , 2013 , 146, 238-43	3.6	21
935	A multimodal approach to investigate biomarkers for psychosis in a clinical setting: the integrative neuroimaging studies in schizophrenia targeting for early intervention and prevention (IN-STEP) project. <i>Schizophrenia Research</i> , 2013 , 143, 116-24	3.6	45
934	Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. 2013 , 210, 387-95		49
933	Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. <i>Schizophrenia Research</i> , 2013 , 146, 224-30	3.6	37
932	Are structural brain abnormalities associated with suicidal behavior in patients with psychotic disorders?. 2013 , 47, 1389-95		73
931	A snapshot of cognitive functioning: deriving a tool for the efficient assessment of cognition in schizophrenia and other chronic psychiatric disorders in a real-world inpatient setting. 2013 , 210, 375-80		5
930	P.1.c.001 Cognitive impairment in children – candidate endophenotypes for schizophrenia. 2013 , 23, S180-S181		
929	Development of brief versions of the Wechsler Intelligence Scale for schizophrenia: considerations of the structure and predictability of intelligence. 2013 , 210, 773-9		8
928	Carbon monoxide feedback in a motivational decision support system for nicotine dependence among smokers with severe mental illnesses. 2013 , 45, 319-24		13
927	Formulation of the age-education index: measuring age and education effects in neuropsychological performance. 2013 , 25, 61-70		23
926	Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. <i>Schizophrenia Research</i> , 2013 , 150, 15-20	3.6	132
925	Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia. 2013 , 6, 86-7		4
924	Direct and mediated effects of cognitive function with multidimensional outcome measures in schizophrenia: the role of functional capacity. 2013 , 35, 882-95		8
923	Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. 2013 , 203, 172-8		66
922	Preserved working memory and altered brain activation in persons at risk for psychosis. 2013 , 170, 1297-307		24
921	Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. 2013 , 170, 1275-84		251

920	Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample. 2013 , 28, 845-58	8
919	Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. 2013 , 201, 680-5	94
918	Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?. 2013 , 39, 417-35	97
917	Implementing cognitive remediation therapy: lessons from two public mental health services. 2013 , 21, 476-80	4
916	Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). 2013 , 170, 1263-74	217
915	Specialized psychosocial treatment plus treatment as usual (TAU) versus TAU for patients with cannabis use disorder and psychosis: the CapOpus randomized trial. 2013 , 43, 1499-510	39
914	Cognitive aspects of schizophrenia. 2013 , 4, 599-608	4
913	Relationship between nicotine dependence and the endophenotype-related trait of cognitive function but not acoustic startle responses in Japanese patients with schizophrenia. 2013 , 28, 220-9	4
912	Applicability of the MATRICS Consensus Cognitive Battery in Singapore. 2013 , 27, 455-69	9
911	Facilitative Effect of Serotonin1A Receptor Agonists on Cognition in Patients with Schizophrenia. 2013 , 20, 357-362	1
910	Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia. 2013 , 9, 1203-8	9
909	Antipsychotic treatments; focus on lurasidone. 2013 , 4, 102	7
908	Cognition as a central illness feature in schizophrenia. 1-23	4
907	Assessment of cognition in schizophrenia treatment studies. 231-246	
906	Assessment of Symptoms and Cognition. 2013 , 7-25	
905	LORETA current source density for duration mismatch negativity and neuropsychological assessment in early schizophrenia. 2013 , 8, e61152	34
904	Reliability and validity of the CogState battery Chinese language version in schizophrenia. 2013 , 8, e74258	23
903	Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. 2013 , 9, 1113-20	36

902	Neurocognitive Functioning in Schizophrenia and Bipolar Disorder: Clarifying Concepts of Diagnostic Dichotomy vs. Continuum. 2013 , 4, 162	26
901	Electrophysiological and neuropsychological predictors of conversion to schizophrenia in at-risk subjects. 2013 , 7, 148	17
900	Deficits in high- (>60 Hz) gamma-band oscillations during visual processing in schizophrenia. 2013 , 7, 88	80
899	Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data. 2013 , 7, 661	57
898	The multi-faceted, global cognitive impairment profile in schizophrenia. 24-49	1
897	A pilot study to evaluate simulated driving performance and cognitive function in healthy subjects and patients with restless legs syndrome. 2013 , 53	2
896	Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone. 2014 , 10, 527-33	23
895	Towards a framework for treatment effectiveness in schizophrenia. 2014 , 10, 1867-78	12
894	Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances. 2014 , 1, 187-192	8
893	Refining the latent structure of neuropsychological performance in schizophrenia. 2014 , 44, 3557-70	13
892	Remote "hovering" with individuals with psychotic disorders and substance use: feasibility, engagement, and therapeutic alliance with a text-messaging mobile interventionist. 2014 , 10, 197-203	47
891	Abnormal GABAergic function and negative affect in schizophrenia. 2014 , 39, 1000-8	18
890	Cognitive deficit awareness in schizophrenia: absent, intact, or somewhere in-between?. 2014 , 19, 471-84	17
889	Association of a miRNA-137 polymorphism with schizophrenia in a Southern Chinese Han population. 2014 , 2014, 751267	24
888	Neurocognitive functioning in patients with first-episode schizophrenia 1 year from onset in comparison with patients 5 years from onset. 2014 , 18, 63-9	8
887	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. 2014 , 4, e004158	16
886	Cognitive impairments in psychotic disorders: common mechanisms and measurement. 2014 , 13, 224-32	100
885	Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls. 2014 , 68, 160-6	15

884	Abnormalities of mental rotation of hands associated with speed of information processing and executive function in chronic schizophrenic patients. 2014 , 68, 410-7		2
883	Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. 2014 , 71, 761-8		50
882	Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial. 2014 , 14, 199		10
881	Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. 2014 , 19 Suppl 1, 38-52; quiz 35-7, 53		83
880	Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. 2014 , 4, 257-67		21
879	Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. 2014 , 71, 769-77		142
878	Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. 2014 , 40, 1244-53		318
877	INECO frontal screening: an instrument to assess executive dysfunction in schizophrenia. 2014 , 17, E19		5
876	Neuropsychological deficits in bipolar depression persist after successful antidepressant treatment. 2014 , 156, 144-9		11
875	Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder. 2014 , 216, 291-302		44
874	Common and specific cognitive deficits in schizophrenia: relationships to function. 2014 , 14, 161-74		36
873	Self-attribution bias during continuous action-effect monitoring in patients with schizophrenia. <i>Schizophrenia Research</i> , 2014 , 152, 33-40	3.6	16
872	Toward a more parsimonious assessment of neurocognition in schizophrenia: a 10-minute assessment tool. 2014 , 52, 50-6		22
871	The Brief Assessment of Cognition In Affective Disorders (BAC-A):performance of patients with bipolar depression and healthy controls. 2014 , 166, 86-92		25
870	Mismatch negativity is a stronger indicator of functional outcomes than neurocognition or theory of mind in patients with schizophrenia. 2014 , 48, 213-9		45
869	Social cognition and neurocognitive deficits in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2014 , 153, 9-17	3.6	60
868	Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. 2014 , 40, 1374-84		67
867	Cognitive remediation in schizophrenia: efficacy and effectiveness in patients with early versus long-term course of illness. 2014 , 8, 32-8		97

866	Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia. 2014 , 68, 425-31		9
865	Effects of Training of Affect Recognition on the recognition and visual exploration of emotional faces in schizophrenia. <i>Schizophrenia Research</i> , 2014 , 159, 485-90	3.6	22
864	Impaired processing speed and attention in first-episode drug naive schizophrenia with deficit syndrome. <i>Schizophrenia Research</i> , 2014 , 159, 478-84	3.6	26
863	Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiarity and relation to generalized cognitive deficit. <i>Schizophrenia Research</i> , 2014 , 159, 491-8	3.6	47
862	Predictors of memory performance among Taiwanese postmenopausal women with heart failure. 2014 , 20, 679-88		2
861	A pilot study to measure cognitive impairment in patients with severe schizophrenia with the Montreal Cognitive Assessment (MoCA). <i>Schizophrenia Research</i> , 2014 , 158, 151-5	3.6	39
860	Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies. <i>Schizophrenia Research</i> , 2014 , 159, 205-10 ^{3.6}		9
859	Differential hedonic experience and behavioral activation in schizophrenia and bipolar disorder. 2014 , 219, 470-6		19
858	Investigation of the Montreal Cognitive Assessment (MoCA) as a cognitive screener in severe mental illness. 2014 , 220, 664-8		36
857	Emotion recognition deficits in schizophrenia-spectrum disorders and psychotic bipolar disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. <i>Schizophrenia Research</i> , 2014 , 158, 105-12	3.6	58
856	Testing trait depression as a potential clinical domain in schizophrenia. <i>Schizophrenia Research</i> , 2014 , 159, 243-8	3.6	21
855	Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. 2014 , 68, 37-49		52
854	Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia. 2015 , 1, 107-120		14
853	Loss of pattern separation performance in schizophrenia suggests dentate gyrus dysfunction. <i>Schizophrenia Research</i> , 2014 , 159, 193-7	3.6	71
852	Relationship between clinical improvement and functional gains with clozapine in schizophrenia. 2014 , 24, 1622-9		5
851	MATRICES cognitive consensus battery (MCCB) performance in children, adolescents, and young adults. <i>Schizophrenia Research</i> , 2014 , 152, 223-8	3.6	16
850	Self-conscious emotions? role in functional outcomes within clinical populations. 2014 , 216, 17-23		5
849	Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment. 2014 , 217, 9-14		46

848	Daily activity patterns in remitted first-episode schizophrenia. 2014 , 55, 1182-7		7
847	A pilot study on the effects of cognitive remediation on hemodynamic responses in the prefrontal cortices of patients with schizophrenia: a multi-channel near-infrared spectroscopy study. <i>Schizophrenia Research</i> , 2014 , 153, 87-95	3.6	24
846	The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naïve persons with schizophrenia seropositive to <i>Toxoplasma gondii</i> . 2014 , 53, 119-24		22
845	Language-dependent performance on the letter fluency task in patients with schizophrenia. <i>Schizophrenia Research</i> , 2014 , 152, 421-9	3.6	6
844	Using the Brief Assessment of Cognition in Schizophrenia (BACS) to assess cognitive impairment in older patients with schizophrenia and bipolar disorder. 2014 , 16, 326-36		21
843	The role of dysfunctional attitudes in models of negative symptoms and functioning in schizophrenia. <i>Schizophrenia Research</i> , 2014 , 157, 182-9	3.6	42
842	Application of the Audio Recorded Cognitive Screen and its relation to functioning in schizophrenia. 2015 , 27, 279-90		
841	Combined social cognitive and neurocognitive rehabilitation strategies in schizophrenia: neuropsychological and psychopathological influences on Theory of Mind improvement. 2015 , 45, 3147-57		28
840	Clinical (but not cognitive) recovery in schizophrenia through the experience of fictional cinema. 2015 , 2, 189-194		1
839	Altered attentional and perceptual processes as indexed by N170 during gaze perception in schizophrenia: Relationship with perceived threat and paranoid delusions. 2015 , 124, 519-531		11
838	Differential patterns of blood oxygenation in the prefrontal cortex between patients with methamphetamine-induced psychosis and schizophrenia. 2015 , 5, 12107		18
837	Functional Outcome in Patients With Schizophrenia: The Concept and Measurement. 2015 , 57, 1-11		6
836	Cognitive impairment in manic bipolar patients: important, understated, significant aspects. 2015 , 14, 41		34
835	Outcome of cognitive performances in bipolar euthymic patients after a depressive episode: a longitudinal naturalistic study. 2015 , 14, 32		6
834	Perfusion shift from white to gray matter may account for processing speed deficits in schizophrenia. 2015 , 36, 3793-804		22
833	Toward Developing a Framework for Standardizing the Functional Assessment and Performance Evaluation of Assistive Robotic Manipulators (ARMs). 2015 , 59, 986-990		1
832	Neurocognitive features in male patients with schizophrenia exhibiting serious violence: a case control study. 2015 , 14, 46		6
831	Assessment of functioning in patients with schizophrenia and schizoaffective disorder with the Mini-ICF-APP: a validation study in Italy. 2015 , 9, 37		11

830	Facial expression perception correlates with verbal working memory function in schizophrenia. 2015 , 69, 773-81	9
829	An abbreviated version of the brief assessment of cognition in schizophrenia (BACS). 2015 , 29, 131-134	3
828	Reliability and Validity of The Turkish Version of Cognitive Assessment Interview (CAI-TR). 2015 , 25, 365-380	9
827	Reliability and validity of the NeuroCognitive Performance Test, a web-based neuropsychological assessment. 2015 , 6, 1652	45
826	Associations between components of metabolic syndrome and cognition in patients with schizophrenia. 2015 , 21, 190-7	20
825	Verbal memory. 2015 , 228, 237-47	3
824	Fronto-limbic novelty processing in acute psychosis: disrupted relationship with memory performance and potential implications for delusions. 2015 , 9, 144	14
823	Cognitive Performance associated to functional outcomes in stable outpatients with schizophrenia. 2015 , 2, 146-158	14
822	Fronto-parietal and cingulo-opercular network integrity and cognition in health and schizophrenia. 2015 , 73, 82-93	109
821	An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. 2015 , 8, 196-200	10
820	[Time perception and schizophrenia: Phenomenological and neuropsychological approach]. 2015 , 41, S56-61	2
819	Detecting syntactic and semantic anomalies in schizophrenia. 2015 , 79, 147-57	28
818	Neurocognitive Profiles of Methamphetamine Users: Comparison of Those With or Without Concomitant Ketamine Use. 2015 , 50, 1778-85	10
817	Cognitive performances associate with measures of white matter integrity in bipolar disorder. 2015 , 174, 342-52	59
816	Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer). 2015 , 41, 233-49	70
815	Effects of lithium on cortical thickness and hippocampal subfield volumes in psychotic bipolar disorder. 2015 , 61, 180-7	62
814	Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users. 2015 , 148, 158-64	33
813	The association between cognitive deficits and depressive symptoms in at-risk mental state: a comparison with first-episode psychosis. <i>Schizophrenia Research</i> , 2015 , 162, 67-73	3.6 19

812	Abnormal movements in first-episode, nonaffective psychosis: dyskinesias, stereotypies, and catatonic-like signs. 2015 , 226, 192-7		28
811	Sensory modulation and daily-life participation in people with schizophrenia. 2015 , 58, 130-7		11
810	The FOCUS trial: cognitive remediation plus standard treatment versus standard treatment for patients at ultra-high risk for psychosis: study protocol for a randomised controlled trial. 2015 , 16, 25		32
809	Clinical Global Impression-severity score as a reliable measure for routine evaluation of remission in schizophrenia and schizoaffective disorders. 2015 , 14, 6		22
808	Simvastatin augmentation for recent-onset psychotic disorder: A study protocol. 2015 , 4, 52-58		11
807	P300 event-related potential in abstinent methamphetamine-dependent patients. 2015 , 149, 142-8		10
806	Alterations in hippocampal connectivity across the psychosis dimension. 2015 , 233, 148-57		60
805	Edge-Centered DTI Connectivity Analysis: Application to Schizophrenia. 2015 , 13, 501-9		5
804	Motivated to do well: an examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. <i>Schizophrenia Research</i> , 2015 , 166, 276-82	3.6	45
803	High velocity circuit resistance training improves cognition, psychiatric symptoms and neuromuscular performance in overweight outpatients with severe mental illness. 2015 , 229, 295-301		35
802	Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS). <i>Schizophrenia Research</i> , 2015 , 164, 8-14	3.6	74
801	Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders. <i>Schizophrenia Research</i> , 2015 , 164, 115-21	3.6	11
800	Glutamate EAAT1 transporter genetic variants influence cognitive deficits in bipolar disorder. 2015 , 226, 407-8		6
799	The impact of genome wide supported microRNA-137 (MIR137) risk variants on frontal and striatal white matter integrity, neurocognitive functioning, and negative symptoms in schizophrenia. 2015 , 168B, 317-26		36
798	Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study. 2015 , 62, 115-22		40
797	Alterations in frontal white matter neurochemistry and microstructure in schizophrenia: implications for neuroinflammation. 2015 , 5, e548		26
796	Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study. 2015 , 14, 1		9
795	Luria revisited: cognitive research in schizophrenia, past implications and future challenges. 2015 , 10, 4		11

794	Cognitive Enhancement. 2015,		
793	Methods for delivering and evaluating the efficacy of cognitive enhancement. 2015, 228, 5-25		2
792	Creativity and positive symptoms in schizophrenia revisited: Structural connectivity analysis with diffusion tensor imaging. <i>Schizophrenia Research</i> , 2015, 164, 221-6	3.6	14
791	Combined neurocognitive and metacognitive rehabilitation in schizophrenia: Effects on bias against disconfirmatory evidence. 2015, 30, 615-21		16
790	Social cognition in patients with schizophrenia spectrum and bipolar disorders with and without psychotic features. 2015, 2, 2-7		8
789	Training of Affect Recognition impacts electrophysiological correlates of facial affect recognition in schizophrenia: Analyses of fixation-locked potentials. 2015, 16, 411-421		3
788	Recuperaci3n Clinica Pero No Cognitiva En Esquizofrenia A Traves De La Experiencia Del Cine De Ficc3n. 2015, 2, 214-219		
787	Protocol for CHANGE: a randomized clinical trial assessing lifestyle coaching plus care coordination versus care coordination alone versus treatment as usual to reduce risks of cardiovascular disease in adults with schizophrenia and abdominal obesity. 2015, 15, 119		10
786	Assisted Cycling Therapy (ACT) improves inhibition in adolescents with autism spectrum disorder. 2015, 40, 376-387		11
785	Abnormal GABAergic function and face processing in schizophrenia: A pharmacologic-fMRI study. <i>Schizophrenia Research</i> , 2015, 168, 338-44	3.6	11
784	Self-reported social functioning and prefrontal hemodynamic responses during a cognitive task in schizophrenia. 2015, 234, 121-9		8
783	Cognitive screening in persons with chronic diseases in primary care: challenges and recommendations for practice. 2015, 30, 547-58		11
782	Improvements in manual dexterity relate to improvements in cognitive planning after assisted cycling therapy (ACT) in adolescents with down syndrome. 2015, 45-46, 261-70		15
781	Examination of the validity of the Brief Neurocognitive Assessment (BNA) for schizophrenia. <i>Schizophrenia Research</i> , 2015, 166, 304-9	3.6	18
780	Correlation between neuropsychological and social cognition measures and symptom dimensions in schizophrenic patients. 2015, 230, 172-80		12
779	Neurocognition, functional competence and self-reported functional impairment in psychometrically defined schizotypy. 2015, 20, 53-63		7
778	Insight and theory of mind in schizophrenia. 2015, 225, 169-174		32
777	Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A). 2015, 60, 81-6		19

776	Measuring cognitive function in MDD: emerging assessment tools. 2015 , 32, 262-9	33
775	COMT and STH polymorphisms interaction on cognition in schizophrenia. 2015 , 36, 215-20	9
774	Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia. 2016 , 12, 2819-2826	18
773	Alpha-Band Oscillations Reflect Altered Multisensory Processing of the McGurk Illusion in Schizophrenia. 2016 , 10, 41	18
772	Positive and Negative Symptoms in Schizophrenia Relate to Distinct Oscillatory Signatures of Sensory Gating. 2016 , 10, 104	14
771	Counterfactual Reasoning Deficits in Schizophrenia Patients. 2016 , 11, e0148440	10
770	Beta/Gamma Oscillations and Event-Related Potentials Indicate Aberrant Multisensory Processing in Schizophrenia. 2016 , 7, 1896	15
769	Abnormal Connectional Fingerprint in Schizophrenia: A Novel Network Analysis of Diffusion Tensor Imaging Data. 2016 , 7, 114	3
768	Current understandings about cognition and the neurobiological correlates in schizophrenia. 2016 , 7, 412-8	21
767	An Individualized Risk Calculator for Research in Prodromal Psychosis. 2016 , 173, 980-988	332
766	Cognitive bias salience in patients with schizophrenia in relation to social functioning: A four-case observation study. 2016 , 5, 36-47	2
765	Deficits of cognitive theory of mind and its relationship with functioning in individuals with an at-risk mental state and first-episode psychosis. 2016 , 243, 318-25	15
764	Reduced frontal theta oscillations indicate altered crossmodal prediction error processing in schizophrenia. 2016 , 116, 1396-407	15
763	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. 2016 , 9, 219-227	3
762	Predictive value of premorbid IQ, negative symptoms, and age for cognitive and social functions in Japanese patients with schizophrenia: A study using the Japanese version of the Brief Assessment of Cognition in Schizophrenia. 2016 , 246, 663-671	9
761	Treatment-Resistant Schizophrenia. 2016 , 39, 239-65	79
760	Emotional Intelligence deficits in schizophrenia: The impact of non-social cognition. <i>Schizophrenia Research</i> , 2016 , 172, 131-6	3.6 19
759	Cognitive Function in Individuals With Psychosis: Moderation by Adolescent Cannabis Use. 2016 , 42, 1496-1503	18

758	Additional support for the cognitive model of schizophrenia: evidence of elevated defeatist beliefs in schizotypy. 2016 , 68, 40-7		19
757	The COMT Val158Met polymorphism moderates the association between cognitive functions and white matter microstructure in schizophrenia. 2016 , 26, 193-202		7
756	Predictors and longitudinal course of cognitive functioning in schizophrenia spectrum disorders, 10years after baseline: The OPUS study. <i>Schizophrenia Research</i> , 2016 , 175, 57-63	3.6	48
755	Neuroscience-informed Auditory Training in Schizophrenia: A Final Report of the Effects on Cognition and Serum Brain-Derived Neurotrophic Factor. 2016 , 3, 1-7		35
754	The relationship between negative symptom subdomains and cognition. 2016 , 46, 2169-77		22
753	Tryptophan Metabolism and White Matter Integrity in Schizophrenia. 2016 , 41, 2587-95		36
752	Impact of duration of untreated psychosis and premorbid intelligence on cognitive functioning in patients with first-episode schizophrenia. <i>Schizophrenia Research</i> , 2016 , 175, 97-102	3.6	21
751	Successful evaluation of cognitive function and the nature of cognitive deficits among people with schizophrenia in clinical rehabilitation settings. 2016 , 24, 342-6		2
750	Randomised controlled trial of a digitally assisted low intensity intervention to promote personal recovery in persisting psychosis: SMART-Therapy study protocol. 2016 , 16, 312		21
749	Neurocognition in patients with schizophrenia. 2016 , 25, 236-247		
748	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. 2016 , 9, 219-227		16
747	Cognitive insight and functional outcome in schizophrenia; a multi-center collaborative study with the specific level of functioning scale-Japanese version. 2016 , 6, 9-14		21
746	Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. 2016 , 6, 308-316		9
745	Ambiguity aversion in schizophrenia: An fMRI study of decision-making under risk and ambiguity. <i>Schizophrenia Research</i> , 2016 , 178, 94-101	3.6	13
744	Usefulness of the Wechsler Intelligence Scale short form for assessing functional outcomes in patients with schizophrenia. 2016 , 245, 371-378		23
743	An examination of the language construct in NIMH's research domain criteria: Time for reconceptualization!. 2016 , 171, 904-19		19
742	The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity. 2016 , 15, 155-65		93
741	The communicative impairment as a core feature of schizophrenia: Frequency of pragmatic deficit, cognitive substrates, and relation with quality of life. 2016 , 71, 106-120		69

740	Life story chapters and narrative self-continuity in patients with schizophrenia. 2016 , 45, 60-74		30
739	Oxytocin Receptor Methylation and Cognition in Psychotic Disorders. 2016 , 2, 151-160		13
738	Neuroplastic Changes Following Social Cognition Training in Schizophrenia: A Systematic Review. 2016 , 26, 310-328		24
737	Diffusion-weighted imaging uncovers likely sources of processing-speed deficits in schizophrenia. 2016 , 113, 13504-13509		30
736	Developing a Virtual Reality-Based Vocational Rehabilitation Training Program for Patients with Schizophrenia. 2016 , 19, 686-691		12
735	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. 2016 , 16, 172		11
734	Development of an Individualized Occupational Therapy Programme and its Effects on the Neurocognition, Symptoms and Social Functioning of Patients with Schizophrenia. 2016 , 23, 425-435		14
733	Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study. 2016 , 17, 553		3
732	Information processing speed mediates the relationship between white matter and general intelligence in schizophrenia. 2016 , 254, 26-33		16
731	Non-verbal speech analysis of interviews with schizophrenic patients. 2016 ,		12
730	Abstinence and Use of Community-Based Cessation Treatment After a Motivational Intervention Among smokers with Severe Mental Illness. 2016 , 52, 446-56		9
729	Relationship between grey matter integrity and executive abilities in aging. 2016 , 1642, 562-580		25
728	Development and usability testing of a web-based smoking cessation treatment for smokers with schizophrenia. 2016 , 4, 113-119		17
727	The effects of cognitive remediation therapy using the frontal/executive program for autism spectrum disorder. 2016 , 51, 223-35		14
726	Characteristics of motivation and their impacts on the functional outcomes in patients with schizophrenia. 2016 , 65, 103-9		11
725	Impulsivity across the psychosis spectrum: Correlates of cortical volume, suicidal history, and social and global function. <i>Schizophrenia Research</i> , 2016 , 170, 80-6	3.6	31
724	The association between cognitive deficits and prefrontal hemodynamic responses during performance of working memory task in patients with schizophrenia. <i>Schizophrenia Research</i> , 2016 , 172, 114-22	3.6	13
723	Callosal Abnormalities Across the Psychosis Dimension: Bipolar Schizophrenia Network on Intermediate Phenotypes. 2016 , 80, 627-35		21

722	Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers. 2016 , 173, 373-84		396
721	Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. <i>Schizophrenia Research</i> , 2016 , 170, 156-61	3.6	24
720	ADDIng a piece to the puzzle of cognition in schizophrenia. 2016 , 59, 26-31		7
719	Healthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers. <i>Schizophrenia Research</i> , 2016 , 172, 106-13	3.6	18
718	Exercise may benefit patients with schizophrenia. 2016 , 14, 103-114		5
717	Motivational Interviewing to Increase Cognitive Rehabilitation Adherence in Schizophrenia. 2016 , 42, 327-34		59
716	Emotional Intelligence and resilience in mental health professionals caring for patients with serious mental illness. 2016 , 21, 755-61		9
715	Disrupted glucocorticoid-Immune interactions during stress response in schizophrenia. 2016 , 63, 86-93		18
714	Evidence for Accelerated Decline of Functional Brain Network Efficiency in Schizophrenia. 2016 , 42, 753-61		29
713	Differential Alterations of Auditory Gamma Oscillatory Responses Between Pre-Onset High-Risk Individuals and First-Episode Schizophrenia. 2016 , 26, 1027-1035		84
712	Screening of Cognitive Impairment in Schizophrenia: Reliability, Sensitivity, and Specificity of the Repeatable Battery for the Assessment of Neuropsychological Status in a Spanish Sample. 2016 , 23, 221-31		11
711	NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. 2017 , 11, 418-428		40
710	Similarity among tasks is the key to show generalization of cognitive training effects in Alzheimer's disease: a case study. 2017 , 24, 247-255		2
709	Validation of the tablet-administered Brief Assessment of Cognition (BAC App). <i>Schizophrenia Research</i> , 2017 , 181, 100-106	3.6	34
708	Cognitive inconsistency in bipolar patients is determined by increased intra-individual variability in initial phase of task performance. 2017 , 210, 222-225		9
707	The Youth Mental Health Risk and Resilience Study (YouR-Study). 2017 , 17, 43		16
706	Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia. 2017 , 27, 12-15		6
705	Association of fronto-temporal function with cognitive ability in schizophrenia. 2017 , 7, 42858		7

704	Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder. 2017 , 76, 12-18	17
703	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. 2017 , 136, 52-62	24
702	Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia. 2017 , 74, 96-101	16
701	Successful implementation of a cognitive remediation program in everyday clinical practice for individuals living with schizophrenia. 2017 , 40, 87-93	8
700	Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology. 2017 , 7, e1087	25
699	Transdiagnostic Associations Between Functional Brain Network Integrity and Cognition. 2017 , 74, 605-613	75
698	Investigating consummatory and anticipatory pleasure across motivation deficits in schizophrenia and healthy controls. 2017 , 254, 112-117	24
697	Is Emotional Intelligence Impaired in Unaffected Siblings of Patients with Schizophrenia?. 2017 , 23, 577-583	2
696	Theory of mind deficits partly mediate impaired social decision-making in schizophrenia. 2017 , 17, 168	6
695	Establishing the Brief Assessment of Cognition - Short form. 2017 , 93, 1-11	2
694	Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study. 2017 , 7, e014938	2
693	Placebo Response and Practice Effects in Schizophrenia Cognition Trials. 2017 , 74, 807-814	29
692	Cardiovascular Pharmacogenomics and Cognitive Function in Patients with Schizophrenia. 2017 , 37, 1122-1130	11
691	A decline in self-defining memories following a diagnosis of schizophrenia. 2017 , 76, 18-25	8
690	Associations between daily living skills, cognition, and real-world functioning across stages of schizophrenia; a study with the Schizophrenia Cognition Rating Scale Japanese version. 2017 , 7, 13-18	21
689	EPICOG-SCH: A brief battery to screen cognitive impact of schizophrenia in stable outpatients. 2017 , 8, 7-20	1
688	Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis. 2017 , 71, 318-327	29
687	Cognitive burden of anticholinergic medications in psychotic disorders. <i>Schizophrenia Research</i> , 2017 , 190, 129-135	3.6 42

686	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. 2017 , 174, 216-229	408
685	Multidimensional cognitive impairment in unipolar and bipolar depression and the moderator effect of adverse childhood experiences. 2017 , 71, 309-317	12
684	Emotional intelligence and non-social cognition in schizophrenia and bipolar I disorder. 2017 , 47, 35-42	16
683	Cost-effectiveness of cognitive remediation and supported employment for people with mental illness: a randomized controlled trial. 2017 , 47, 53-65	29
682	The Chinese Version of the Brief Assessment of Cognition in Schizophrenia: Data of a Large-Scale Mandarin-Speaking Population. 2017 , 32, 289-296	16
681	Disengagement from tasks as a function of cognitive load and depressive symptom severity. 2017 , 22, 83-94	12
680	Negative symptoms mediate the relationship between neurocognition and function in individuals at ultrahigh risk for psychosis. 2017 , 135, 250-258	17
679	The effect of duration of untreated psychosis and treatment delay on the outcomes of prolonged early intervention in psychotic disorders. 2017 , 3, 34	45
678	The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia. 2017 , 37, 651-656	24
677	Cognitive clustering in schizophrenia patients, their first-degree relatives and healthy subjects is associated with anterior cingulate cortex volume. 2017 , 16, 248-256	31
676	Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. 2017 , 7, e1215	46
675	Association between cognitive deficits and suicidal ideation in patients with major depressive disorder. 2017 , 7, 11637	50
674	Working memory and prefrontal/temporal hemodynamic responses during post-task period in patients with schizophrenia: A multi-channel near-infrared spectroscopy study. 2017 , 95, 288-298	13
673	Cognitive function, treatment response to lithium, and social functioning in Japanese patients with bipolar disorder. 2017 , 19, 552-562	8
672	The effect of the muscarinic M receptor antagonist biperiden on cognition in medication free subjects with psychosis. 2017 , 27, 854-864	11
671	Ineffective initiation contributes to deficient verbal and non-verbal fluency in patients with schizophrenia. 2017 , 22, 391-406	11
670	Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia. 2017 , 174, 1195-1202	38
669	Targeting anxiety to improve quality of life in patients with schizophrenia. 2017 , 45, 129-135	16

668	Association between the scores of the Japanese version of the Brief Assessment of Cognition in Schizophrenia and whole-brain structure in patients with chronic schizophrenia: A voxel-based morphometry and diffusion tensor imaging study. 2017 , 71, 826-835	14
667	Association of White Matter With Core Cognitive Deficits in Patients With Schizophrenia. 2017 , 74, 958-966	71
666	Quality of life in individuals with attenuated psychotic symptoms: Possible role of anxiety, depressive symptoms, and socio-cognitive impairments. 2017 , 257, 431-437	17
665	Convergence and Divergence of Brain Network Dysfunction in Deficit and Non-deficit Schizophrenia. 2017 , 43, 1315-1328	22
664	Testing a decades' old assumption: Are individuals with lower sensory gating indeed more easily distracted?. 2017 , 255, 387-393	3
663	Comparison of neurocognitive function in major depressive disorder, bipolar disorder, and schizophrenia in later life: A cross-sectional study of euthymic or remitted, non-demented patients using the Japanese version of the Brief Assessment of Cognition in Schizophrenia (BACS-J). 2017 , 254, 205-210	25
662	Association between social functioning and prefrontal cortex function during a verbal fluency task in schizophrenia: A near-infrared spectroscopic study. 2017 , 71, 769-779	17
661	Joint prediction of multiple scores captures better individual traits from brain images. 2017 , 158, 145-154	24
660	The role of white matter microstructure in inhibitory deficits in patients with schizophrenia. 2017 , 10, 283-290	9
659	The effect of positive symptoms on social cognition in first-episode schizophrenia is modified by the presence of negative symptoms. 2017 , 31, 209-219	29
658	Neural complexity as a potential translational biomarker for psychosis. 2017 , 216, 89-99	27
657	Course of illness in a sample of patients diagnosed with a schizotypal disorder and treated in a specialized early intervention setting. Findings from the 3.5year follow-up of the OPUS II study. <i>Schizophrenia Research</i> , 2017 , 182, 24-30	3.6 13
656	Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study. 2017 , 29, 72-79	41
655	Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. 2017 , 267, 163-171	22
654	Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy. 2017 , 18, 401-408	28
653	Cognitive remediation and functional improvement in schizophrenia: Is it a matter of size?. 2017 , 40, 26-32	20
652	Infection and inflammation in schizophrenia and bipolar disorder. 2017 , 115, 59-63	36
651	The longitudinal trajectory of serum brain-derived neurotrophic factor (BDNF) levels in psychotic patients: a prospective observational study. 2017 , 27, S913	2

650	Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II). 2017 , 356, i6681	53
649	Manual Dexterity in Schizophrenia-A Neglected Clinical Marker?. 2017 , 8, 120	7
648	Verbal Memory Impairment in Patients with Subsyndromal Bipolar Disorder. 2017 , 8, 168	10
647	Raloxifene Improves Cognition in Schizophrenia: Spurious Result or Valid Effect?. 2017 , 8, 202	13
646	Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants. 2017 , 76, 209-221	7
645	Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. 2017 , 18,	11
644	Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia. 2017 , 8, 71-81	7
643	Effect of lifestyle coaching versus care coordination versus treatment as usual in people with severe mental illness and overweight: Two-years follow-up of the randomized CHANGE trial. 2017 , 12, e0185881	19
642	TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial. 2017 , 18, 445	14
641	The CapOpus Trial for Cannabis Use Disorders. 2017 , 1086-1092	
640	Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia. 2018 , 43, 1675-1680	24
639	Processing Speed is Impaired in Adults with Autism Spectrum Disorder, and Relates to Social Communication Abilities. 2018 , 48, 2653-2662	32
638	Distinct patterns of blood oxygenation in the prefrontal cortex in clinical phenotypes of schizophrenia and bipolar disorder. 2018 , 234, 45-53	5
637	Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - Baseline and two-years findings from the CHANGE trial. <i>Schizophrenia Research</i> , 2018 , 199, 96-102	3.6 24
636	What accounts for poor functioning in people with schizophrenia: a re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors. 2018 , 48, 2776-2785	29
635	Empirical evidence for discrete neurocognitive subgroups in patients with non-psychotic major depressive disorder: clinical implications. 2018 , 48, 2717-2729	20
634	Disrupted modular organization of primary sensory brain areas in schizophrenia. 2018 , 18, 682-693	27
633	Associations between adolescent cannabis use and brain structure in psychosis. 2018 , 276, 53-64	10

632	Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. 2018 , 8, 78		30
631	Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia. 2018 , 263, 54-60		12
630	A Case Study of Clozapine and Cognition: Friend or Foe?. 2018 , 38, 152-153		2
629	Sleep endophenotypes of schizophrenia: slow waves and sleep spindles in unaffected first-degree relatives. 2018 , 4, 2		23
628	The relationship of categorical and phonological verbal fluency to negative schizotypy and social functioning in a non-clinical sample. 2018 , 23, 43-57		4
627	Cognitive Predictors of Work Among Social Security Disability Insurance Beneficiaries With Psychiatric Disorders Enrolled in IPS Supported Employment. 2018 , 44, 32-37		14
626	Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls. 2018 , 235, 2113-2121		18
625	Multivariate Relationships Between Cognition and Brain Anatomy Across the Psychosis Spectrum. 2018 , 3, 992-1002		13
624	Altered functional connectivity strength and its correlations with cognitive function in subjects with ultra-high risk for psychosis at rest. 2018 , 24, 1140-1148		17
623	The Relationship of Motivation and Neurocognition with Functionality in Schizophrenia: A Meta-analytic Review. 2018 , 54, 1019-1049		13
622	Comparing predictors of employment in Individual Placement and Support: A longitudinal analysis. 2018 , 264, 85-90		14
621	Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2018 , 199, 395-402	3.6	50
620	Montreal Cognitive Assessment as a screening instrument for cognitive impairments in schizophrenia. <i>Schizophrenia Research</i> , 2018 , 199, 58-63	3.6	27
619	Cognitive Reserve Profiles in Chronic Schizophrenia: Effects on Theory of Mind Performance and Improvement after Training. 2018 , 24, 563-571		13
618	Dietary patterns and physical activity in people with schizophrenia and increased waist circumference. <i>Schizophrenia Research</i> , 2018 , 199, 109-115	3.6	33
617	Disturbed functional connectivity within the left prefrontal cortex and sensorimotor areas predicts impaired cognitive speed in patients with first-episode schizophrenia. 2018 , 275, 28-35		22
616	Feasibility and effectiveness of a cognitive remediation programme with original computerised cognitive training and group intervention for schizophrenia: a multicentre randomised trial. 2018 , 28, 387-397		8
615	Feasibility and effectiveness of cognitive remediation in the treatment of borderline personality disorder. 2018 , 28, 416-428		8

614	A Case Study of the Long-Lasting Effects of Cognitive Training on Similar Tasks in Alzheimer's Disease. 2018 , 37, 1215-1224		1
613	Visual and audio emotion processing training for outpatients with schizophrenia: an integrated multisensory approach. 2018 , 28, 1131-1144		4
612	The relationship between cognitive insight and cognitive performance among individuals with at-risk mental state for developing psychosis. <i>Schizophrenia Research</i> , 2018 , 192, 281-286	3.6	16
611	Increased serum levels of cysteine in patients with schizophrenia: A potential marker of cognitive function preservation. <i>Schizophrenia Research</i> , 2018 , 192, 391-397	3.6	12
610	Deviation from expected cognitive ability across psychotic disorders. <i>Schizophrenia Research</i> , 2018 , 192, 300-307	3.6	13
609	Integrated cognitive remediation and standard rehabilitation therapy in patients of schizophrenia: persistence after 5years. <i>Schizophrenia Research</i> , 2018 , 192, 335-339	3.6	28
608	Demographic and clinical correlates of substance use disorders in first episode psychosis. <i>Schizophrenia Research</i> , 2018 , 194, 4-12	3.6	44
607	Demographic, psychosocial, clinical, and neurocognitive baseline characteristics of Black Americans in the RAISE-ETP study. <i>Schizophrenia Research</i> , 2018 , 193, 64-68	3.6	13
606	Glutamatergic Response to Heat Pain Stress in Schizophrenia. 2018 , 44, 886-895		5
605	Olfactory deficits in individuals at risk for psychosis and patients with schizophrenia: relationship with socio-cognitive functions and symptom severity. 2018 , 268, 689-698		10
604	Objective assessment of exploratory behaviour in schizophrenia using wireless motion capture. <i>Schizophrenia Research</i> , 2018 , 195, 122-129	3.6	1
603	Impaired self-agency inferences in schizophrenia: The role of cognitive capacity and causal reasoning style. 2018 , 47, 27-34		1
602	Association between mismatch negativity and global functioning is specific to duration deviance in early stages of psychosis. <i>Schizophrenia Research</i> , 2018 , 195, 378-384	3.6	23
601	Prospective Relationships Between Motivation and Functioning in Recovery After a First Episode of Schizophrenia. 2018 , 44, 369-377		22
600	Association of obesity with cognitive function and brain structure in patients with major depressive disorder. 2018 , 225, 188-194		23
599	Differentiating bipolar disorders from unipolar depression by applying the Brief Assessment of Cognition in Affective Disorders. 2018 , 48, 929-938		9
598	Achieving recovery in patients with schizophrenia through psychosocial interventions: A retrospective study. 2018 , 72, 28-34		15
597	A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS). <i>Schizophrenia Research</i> , 2018 , 195, 327-333	3.6	5

596	Pregabalin for anxiety in patients with schizophrenia - A randomized, double-blind placebo-controlled study. <i>Schizophrenia Research</i> , 2018 , 195, 260-266	3.6	8
595	Cognitive deficit in patients with paranoid schizophrenia: Its clinical and laboratory correlates. 2018 , 262, 542-548		21
594	Eye gaze perception in bipolar disorder: Self-referential bias but intact perceptual sensitivity. 2018 , 20, 60-69		11
593	Investigating the predictors of happiness, life satisfaction and success in schizophrenia. 2018 , 81, 42-47		13
592	The Chinese version of the Brief Assessment of Cognition in Affective Disorders: normative data of a Mandarin-speaking population. 2018 , 32, 1-14		4
591	The Screen for Cognitive Impairment in Psychiatry: Proposal for a polytomous scoring system. 2018 , 27, e1598		9
590	Improving neurocognitive functioning in schizophrenia by addition of cognitive remediation therapy to a standard treatment of metacognitive training. 2018 , 10, 7812		3
589	Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning. 2018 , 61, 91-102		33
588	Pituitary Volume and Socio-Cognitive Functions in Individuals at Risk of Psychosis and Patients With Schizophrenia. 2018 , 9, 574		5
587	Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). 2018 , 5, 216-234		13
586	Therapeutic responses to a frontal/executive programme in autism spectrum disorder: Comparison with schizophrenia. 2018 , 31, 69-75		
585	Gender differences in the relationships among neurosteroid serum levels, cognitive function, and quality of life. 2018 , 14, 2389-2399		7
584	Hippocampal subregion abnormalities in schizophrenia: A systematic review of structural and physiological imaging studies. 2018 , 38, 156-166		40
583	Association of the Synapse-Associated Protein 97 () Gene Polymorphism With Neurocognitive Function in Schizophrenic Patients. 2018 , 9, 458		9
582	Predictors of cognitive performance in bipolar disorder: The role of educational degree and inflammatory markers. 2018 , 106, 31-37		17
581	Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. 2018 , 4, 22		27
580	Neurocognitive and theory of mind deficits and poor social competence in schizophrenia: The moderating role of social disinterest attitudes. 2018 , 270, 459-466		9
579	Themes of unfulfilled agency and communion in life stories of patients with schizophrenia. 2018 , 269, 772-778		11

578	Cognitive Function Is Impaired in Patients with Recently Diagnosed Type 2 Diabetes, but Not Type 1 Diabetes. 2018 , 2018, 1470476		12
577	The Role of Executive Function in Adolescent Adaptive Risk-Taking on the Balloon Analogue Risk Task. 2018 , 43, 566-580		14
576	Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. 2018 , 79,		15
575	Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. <i>Schizophrenia Research</i> , 2018 , 201, 85-90	3.6	7
574	Could schizoaffective disorder, schizophrenia and bipolar I disorder be distinguishable using cognitive profiles?. 2018 , 266, 79-84		7
573	Effect of cognitive function on jumping to conclusion in patients with schizophrenia. 2018 , 12, 50-55		8
572	Objective investigation of activity preference in schizophrenia: A pilot study. 2018 , 267, 551-559		0
571	Exploring anxiety in schizophrenia: New light on a hidden figure. 2018 , 268, 312-316		9
570	Glutamate Concentration in the Superior Temporal Sulcus Relates to Neuroticism in Schizophrenia. 2018 , 9, 578		1
569	Semantic Memory Organization in Japanese Patients With Schizophrenia Examined With Category Fluency. 2018 , 9, 87		7
568	Relationship of Handgrip Strength and Body Mass Index With Cognitive Function in Patients With Schizophrenia. 2018 , 9, 156		15
567	The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients. 2018 , 9, 232		9
566	Electrophysiological Evidence in Schizophrenia in Relation to Treatment Response. 2018 , 9, 259		1
565	Impaired visual, working, and verbal memory in first-episode, drug-naive patients with major depressive disorder in a Chinese population. 2018 , 13, e0196023		11
564	Predicting work outcome in patients with schizophrenia: Influence of IQ decline. <i>Schizophrenia Research</i> , 2018 , 201, 172-179	3.6	8
563	[Evaluation of a neuropsychological test battery with psychiatric and psychosomatic patients]. 2018 , 86, 348-355		
562	Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism. <i>Schizophrenia Research</i> , 2018 , 202, 106-110	3.6	9
561	Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia. 2018 , 43, 1706-1711		16

560	Alterations of Intrinsic Connectivity Networks in Antipsychotic-Naïve First-Episode Schizophrenia. 2018 , 44, 1332-1340	13
559	Structural equation modeling approach between salience network dysfunction, depressed mood, and subjective quality of life in schizophrenia: an ICA resting-state fMRI study. 2018 , 14, 1585-1597	7
558	Serum levels of β -hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study. 2018 , 14, 799-808	3
557	Motor clusters reveal differences in risk for psychosis, cognitive functioning, and thalamocortical connectivity: evidence for vulnerability subtypes. 2018 , 6, 721-734	34
556	A multicenter, randomized controlled trial of individualized occupational therapy for patients with schizophrenia in Japan. 2018 , 13, e0193869	14
555	Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers. 2018 , 16, 225-236	2
554	Cognitive effects of bilateral high frequency repetitive transcranial magnetic stimulation in early phase psychosis: a pilot study. 2019 , 13, 852-861	20
553	Using Online Screening in the General Population to Detect Participants at Clinical High-Risk for Psychosis. 2019 , 45, 600-609	32
552	Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial. 2019 , 49, 1138-1147	6
551	Cognitive remediation in large systems of psychiatric care. 2019 , 24, 163-173	8
550	Validation of the Danish version of the brief negative symptom scale. 2019 , 73, 425-432	10
549	Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for anti gliadin antibodies (AGA IgG): a pilot feasibility study. 2019 , 44, 269-276	12
548	Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial. 2019 , 76, 1009-1017	13
547	Clinical and genetic determinants of serum brain-derived neurotrophic factor (BDNF) levels in psychotic patients: A longitudinal prospective study. 2019 , 29, S133-S134	
546	Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): a feasibility study. 2019 , 5, 79	
545	Properties and performance of photocatalytic CeO ₂ , TiO ₂ , and CeO ₂ /TiO ₂ layered thin films. 2019 , 45, 22085-22094	11
544	Relationship of auditory electrophysiological responses to magnetic resonance spectroscopy metabolites in Early Phase Psychosis. 2019 , 145, 15-22	7
543	Abnormalities in hubs location and nodes centrality predict cognitive slowing and increased performance variability in first-episode schizophrenia patients. 2019 , 9, 9594	17

542	Functional network connectivity impairments and core cognitive deficits in schizophrenia. 2019 , 40, 4593-4605	22
541	Metabolic syndrome is negatively associated with cognition among endothelial nitric oxide synthase (eNOS)- 786C carriers in schizophrenia-spectrum disorders. 2019 , 117, 142-147	2
540	External validation and extension of the NAPLS-2 and SIPS-RC personalized risk calculators in an independent clinical high-risk sample. 2019 , 279, 9-14	18
539	Association between olfactory sulcus morphology and olfactory functioning in schizophrenia and psychosis high-risk status. 2019 , 5, e02642	3
538	40-Hz auditory steady-state responses and the complex information processing: An exploratory study in healthy young males. 2019 , 14, e0223127	4
537	Using a Smartphone App to Identify Clinically Relevant Behavior Trends Symptom Report, Cognition Scores, and Exercise Levels: A Case Series. 2019 , 10, 652	32
536	Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. 2019 , 11,	27
535	Aerobic exercise and cognitive functioning in schizophrenia: A pilot randomized controlled trial. 2019 , 282, 112638	12
534	Computer-assisted cognitive remediation therapy for patients with schizophrenia induces microstructural changes in cerebellar regions involved in cognitive functions. 2019 , 292, 41-46	3
533	Long-Range Temporal Correlations in Resting State Beta Oscillations are Reduced in Schizophrenia. 2019 , 10, 517	7
532	The Feasibility and Efficacy of Social Cognition and Interaction Training for Outpatients With Schizophrenia in Japan: A Multicenter Randomized Clinical Trial. 2019 , 10, 589	2
531	Formative, multimethod case studies of learn to quit, an acceptance and commitment therapy smoking cessation app designed for people with serious mental illness. 2019 , 9, 1076-1086	9
530	Association of genetic variants at 22q11.2 chromosomal region with cognitive performance in Japanese patients with schizophrenia. 2019 , 17, 100134	
529	The brief assessment of cognition in affective disorders: Normative data for the Italian population. 2019 , 252, 245-252	4
528	Schizophrenia Exhibits Bi-directional Brain-Wide Alterations in Cortico-Striato-Cerebellar Circuits. 2019 , 29, 4463-4487	11
527	Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). <i>Schizophrenia Research</i> , 2019 , 210, 30-38	3.6 3
526	Foreword. 2019 , ix-x	
525	Cognition and Its Impairment in Schizophrenia and Related Psychotic Disorders. 2019 , 1-17	

524 Index. **2019**, 179-184

523 Effect of adding individualized occupational therapy to standard care on rehospitalization of patients with schizophrenia: A 2-year prospective cohort study. **2019**, 73, 476-485 4

522 Preface. **2019**, xi-xii

521 Attenuated mismatch negativity in patients with first-episode antipsychotic-naïve schizophrenia using a source-resolved method. **2019**, 22, 101760 6

520 Towards remote digital phenotyping of cognition in schizophrenia. *Schizophrenia Research*, **2019**, 208, 36-38 3.6 9

519 The Brain That Builds Itself. **2019**, 18-30

518 Cognitive Enhancement. **2019**, 31-44

517 Getting Ready for Cognitive Enhancement. **2019**, 45-57

516 Computer-based Approaches to Cognitive Enhancement. **2019**, 58-71

515 Individual and Group Approaches to Cognitive Enhancement. **2019**, 72-89

514 Psychopharmacological Approaches, Cognitive Enhancement, and Brain Stimulation. **2019**, 90-102 1

513 Who Responds Best? Predictors and Moderators of Cognitive Enhancement. **2019**, 103-114

512 Choosing the Right Treatment for the Right Patient. **2019**, 115-127

511 Approaches to Assessment and Monitoring Treatment Response. **2019**, 128-137

510 Research in Cognitive Enhancement. **2019**, 138-150

509 Glossary. **2019**, 151-154

508 References. **2019**, 155-178

507 Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. **2019**, 142, 1813-1826 32

506	Competence to Consent and Its Relationship With Cognitive Function in Patients With Schizophrenia. 2019 , 10, 195		5
505	Understanding software developers' cognition in agile requirements engineering. 2019 , 178, 1-19		5
504	Response to: Bryce and Allott - Cognitive screening: A significant unmet need in youth mental health. 30 minutes is too long!. 2019 , 53, 814		1
503	The interactive effects of stress and coping style on cognitive function in patients with schizophrenia. 2019 , 15, 523-530		1
502	Severe childhood trauma and clinical and neurocognitive features in schizotypal personality disorder. 2019 , 140, 50-64		14
501	Social anxiety and negative symptoms as the characteristics of patients with schizophrenia who show competence-performance discrepancy in social functioning. 2019 , 73, 394-399		6
500	EEG correlates of face recognition in patients with schizophrenia spectrum disorders: A systematic review. 2019 , 130, 986-996		12
499	Cognitive functioning as a predictor of response to comprehensive cognitive remediation. 2019 , 113, 117-124		19
498	Effects of illness duration on cognitive performances in bipolar depression are mediated by white matter microstructure. 2019 , 249, 175-182		11
497	Schizophrenia, cannabis use and Catechol-O-Methyltransferase (COMT): Modeling the interplay on cognition. 2019 , 92, 363-368		8
496	Negative and positive self-thoughts predict subjective quality of life in people with schizophrenia. 2019 , 15, 293-301		5
495	An integrated neurocognitive and social-cognitive treatment for youth at clinical high risk for psychosis: Cognition for Learning and for Understanding Everyday Social Situations (CLUES). <i>Schizophrenia Research</i> , 2019 , 208, 55-59	3.6	6
494	The validation of a new online cognitive assessment tool: The MyCognition Quotient. 2019 , 28, e1775		16
493	Insight Into Illness and Defense Styles in Schizophrenia. 2019 , 207, 815-819		6
492	European violence risk and mental disorders (EU-VIORMED): a multi-centre prospective cohort study protocol. 2019 , 19, 410		6
491	Assessment of People with Psychotic and Bipolar Disorders. 2019 , 360-370		
490	Daily Functioning in Schizophrenia: Is There Room for Anxiety?. 2019 , 207, 615-619		3
489	Assessing Cognition Outside of the Clinic: Smartphones and Sensors for Cognitive Assessment Across Diverse Psychiatric Disorders. 2019 , 42, 611-625		12

488	Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients. 2019 , 49, 2754-2763		10
487	Potential role of orbitofrontal surface morphology on social and cognitive functions in high-risk subjects for psychosis and schizophrenia patients. 2019 , 283, 92-95		6
486	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2019 , 206, 67-74	3.6	25
485	Reward-driven decision-making impairments in schizophrenia. <i>Schizophrenia Research</i> , 2019 , 206, 277-283	3.6	13
484	Goal-directed planning and action impairments in schizophrenia evaluated in a virtual environment. <i>Schizophrenia Research</i> , 2019 , 206, 400-406	3.6	5
483	Do patients with high-functioning autism have similar social cognitive deficits as patients with a chronic cause of schizophrenia?. 2019 , 73, 44-50		5
482	Self-defining Memories Predict Engagement in Structured Activity in First Episode Psychosis, Independent of Neurocognition and Metacognition. 2019 , 45, 1081-1091		6
481	Clinical Cases in Psychiatry: Integrating Translational Neuroscience Approaches. 2019 ,		1
480	The Value of Neurocognitive Assessment for Diagnosis and Treatment in Schizophrenic Spectrum Disorders. 2019 , 333-343		
479	From cognitive and clinical substrates to functional profiles: Disentangling heterogeneity in schizophrenia. 2019 , 271, 446-453		7
478	Comparison of prefrontal hemodynamic responses and cognitive deficits between adult patients with autism spectrum disorder and schizophrenia. <i>Schizophrenia Research</i> , 2019 , 206, 420-427	3.6	7
477	Healthy Adolescent Performance With Standardized Scoring Tables for the MATRICS Consensus Cognitive Battery: A Multisite Study. 2019 , 45, 773-783		13
476	Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia. <i>Schizophrenia Research</i> , 2019 , 204, 155-161	3.6	8
475	Brief executive function training for individuals with severe mental illness: Effects on EEG synchronization and executive functioning. <i>Schizophrenia Research</i> , 2019 , 203, 32-40	3.6	13
474	Effects of cognitive remediation on cognitive and social functions in individuals with schizophrenia. 2019 , 29, 1475-1487		9
473	Do attentional capacities and processing speed mediate the effect of age on executive functioning?. 2019 , 26, 282-317		3
472	The role of premorbid adjustment in schizophrenia: Focus on cognitive remediation outcome. 2019 , 29, 1611-1624		7
471	Investigation of sleep spindle activity and morphology as predictors of neurocognitive functioning in medicated patients with schizophrenia. 2019 , 28, e12672		8

470	Factor Structure of the CVLT-II Short Form: Evidence From a Trauma-Exposed Sample. 2019 , 26, 976-983		2
469	Exploring predictors of work competence in schizophrenia: The role of theory of mind. 2019 , 29, 691-703		6
468	Cognitive impairment in psychiatric patients in the United Arab Emirates. 2020 , 27, 87-93		1
467	Training engagement, baseline cognitive functioning, and cognitive gains with computerized cognitive training: A cross-diagnostic study. 2020 , 19, 100150		9
466	Early childhood social communication deficits in youth at clinical high-risk for psychosis: Associations with functioning and risk. 2020 , 32, 559-572		6
465	Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. 2020 , 14, 106-114		10
464	Cingulum and abnormal psychological stress response in schizophrenia. 2020 , 14, 548-561		2
463	The Impact of Childhood Adversity on Cognitive Development in Schizophrenia. 2020 , 46, 140-153		11
462	Metacognition moderates the relationship between self-reported and clinician-rated motivation in schizophrenia. 2020 , 19, 100140		3
461	Neuropsychological deficits in participants at clinical high risk for psychosis recruited from the community: relationships to functioning and clinical symptoms. 2020 , 50, 77-85		8
460	Poor functional recovery is better predicted than conversion in studies of outcomes of clinical high risk of psychosis: insight from SHARP. 2020 , 50, 1578-1584		7
459	Abnormal perfusion fluctuation and perfusion connectivity in bipolar disorder measured by dynamic arterial spin labeling. 2020 , 22, 401-410		2
458	Characterizing functional regional homogeneity (ReHo) as a B-SNIP psychosis biomarker using traditional and machine learning approaches. <i>Schizophrenia Research</i> , 2020 , 215, 430-438	3.6	13
457	Relationship of Metacognition and Insight to Neural Synchronization and Cognitive Function in Early Phase Psychosis. 2020 , 51, 259-266		8
456	Predicting psychosis risk using a specific measure of cognitive control: a 12-month longitudinal study. 2020 , 50, 2230-2239		5
455	The Influence of Premorbid Adjustment and Autistic Traits on Social Cognitive Dysfunction in Schizophrenia. 2020 , 26, 276-285		9
454	The neurophenomenology of early psychosis: An integrative empirical study. 2020 , 77, 102845		25
453	Pilot Randomized Controlled Trial of a Novel Smoking Cessation App Designed for Individuals With Co-Occurring Tobacco Use Disorder and Serious Mental Illness. 2020 , 22, 1533-1542		14


452	Is Utena's Brief Objective Measures (UBOM) useful in real-world behavioral assessment of functioning? Validity and utility testing in patients with schizophrenia. 2020 , 74, 40-48		1
451	Basic symptoms influence real-life functioning and symptoms in individuals at high risk for psychosis. 2020 , 141, 231-240		3
450	Screening for cognitive impairment in non-affective psychoses: A comparison between the SCIP and the MoCA. <i>Schizophrenia Research</i> , 2020 , 218, 188-194	3.6	7
449	Measuring movements in adolescents with psychosis using the Microsoft Kinect sensor: a pilot study exploring a new tool for assessing aspects of antipsychotic-induced parkinsonism. 2020 , 25, 79-94		
448	The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study. 2020 , 37, 753-771		19
447	Genome-wide association study of cognitive performance in U.S. veterans with schizophrenia or bipolar disorder. 2020 , 183, 181-194		9
446	The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment. 2020 , 74, 187-193		12
445	Relationship of prolonged acoustic startle latency to diagnosis and biotype in the bipolar-schizophrenia network on intermediate phenotypes (B-SNIP) cohort. <i>Schizophrenia Research</i> , 2020 , 216, 357-366	3.6	5
444	Meta-analysis of randomised controlled trials with -acetylcysteine in the treatment of schizophrenia. 2020 , 54, 453-466		26
443	A longitudinal comparison of two neurocognitive test batteries in patients with schizophrenia and healthy volunteers: Time effects on neuropsychological performance and their relation to functional outcome. <i>Schizophrenia Research</i> , 2020 , 216, 347-356	3.6	4
442	Utility of the MoCA for cognitive impairment screening in long-term psychosis patients. <i>Schizophrenia Research</i> , 2020 , 216, 429-434	3.6	7
441	The association of autistic traits with Theory of Mind and its training efficacy in patients with schizophrenia. 2020 , 19, 100164		3
440	Association of circadian properties of temporal processing with rapid antidepressant response to wake and light therapy in bipolar disorder. 2020 , 263, 72-79		1
439	Brain functional connectivity data enhance prediction of clinical outcome in youth at risk for psychosis. 2020 , 26, 102108		9
438	Grey-matter abnormalities in clinical high-risk participants for psychosis. <i>Schizophrenia Research</i> , 2020 , 226, 120-128	3.6	1
437	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. 2020 , 124, 103527		7
436	Impact of changes in social anxiety on social functioning and quality of life in outpatients with schizophrenia: A naturalistic longitudinal study. 2020 , 131, 15-21		5
435	Multivariate relationships between peripheral inflammatory marker subtypes and cognitive and brain structural measures in psychosis. 2021 , 26, 3430-3443		18

434	Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. 2021 , 15, 874-881		3
433	The psychometric properties of the Self-Evaluation of Negative Symptoms Scale (SNS) in treatment-resistant schizophrenia (TRS). <i>Schizophrenia Research</i> , 2020 , 224, 159-166	3.6	5
432	Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trial. <i>Schizophrenia Research</i> , 2020 , 224, 151-158	3.6	10
431	SAP97 rs3915512 Polymorphism Affects the Neurocognition of Schizophrenic Patients: A Genetic Neuroimaging Study. 2020 , 11, 572414		1
430	Organized Resting-state Functional Dysconnectivity of the Prefrontal Cortex in Patients with Schizophrenia. 2020 , 446, 14-27		1
429	Randomised controlled trial of Compensatory Cognitive Training and a Computerised Cognitive Remediation programme. 2020 , 21, 810		
428	The relationship between cannabis use and cognition in people diagnosed with first-episode psychosis. 2020 , 293, 113424		3
427	Self-perceived cognitive impairments in psychosis ultra-high risk individuals: associations with objective cognitive deficits and functioning. 2020 , 6, 31		0
426	Deriving symptom networks from digital phenotyping data in serious mental illness. 2020 , 6, e135		4
425	Assessment of brain cholesterol metabolism biomarker 24S-hydroxycholesterol in schizophrenia. 2020 , 6, 34		5
424	Altered Autonomic Function in Individuals at Clinical High Risk for Psychosis. 2020 , 11, 580503		1
423	Perfectionism and Pain Intensity in Women with Fibromyalgia: Its Influence on Activity Avoidance from The Contextual Perspective. 2020 , 17,		1
422	Targeting Serotonin 5-HT Receptors to Better Treat Schizophrenia: Rationale and Current Approaches. 2020 , 34, 947-959		9
421	The genetic variations in SAP97 gene and the risk of schizophrenia in the Chinese Han population: a further study. 2020 , 30, 110-118		3
420	Deficits in Auditory and Visual Sensory Discrimination Reflect a Genetic Liability for Psychosis and Predict Disruptions in Global Cognitive Functioning. 2020 , 11, 638		6
419	Distinguishing patterns of impairment on inhibitory control and general cognitive ability among bipolar with and without psychosis, schizophrenia, and schizoaffective disorder. <i>Schizophrenia Research</i> , 2020 , 223, 148-157	3.6	3
418	Neurocognitive and social cognitive training for youth at clinical high risk (CHR) for psychosis: A randomized controlled feasibility trial. <i>Schizophrenia Research</i> , 2020 ,	3.6	3
417	Cognitive Impairment and Diminished Neural Responses Constitute a Biomarker Signature of Negative Symptoms in Psychosis. 2020 ,		8

416	INTREPID II: protocol for a multistudy programme of research on untreated psychosis in India, Nigeria and Trinidad. 2020 , 10, e039004	5
415	Examining Potential Barriers to mHealth Implementation and Engagement in Schizophrenia: Phone Ownership and Symptom Severity.. 2022 , 7, 13-22	3
414	The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and μ and κ Opioid Receptors Are Associated with Interleukin-6. 2020 , 10,	7
413	Brain of Thrones: Cognitive Effort and Perceived Performance During a Cognitive Task in Major Depressive Disorder. 2020 , 45, 986	1
412	Mismatch Negativity Predicts Remission and Neurocognitive Function in Individuals at Ultra-High Risk for Psychosis. 2020 , 11, 770	6
411	A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data. 2020 , 10, 276	7
410	Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia. 2021 , 15, 1802-1814	4
409	Emotional intelligence in bipolar-I-disorder: A comparison between patients, unaffected siblings, and control subjects. 2020 , 63, e69	3
408	Both unmedicated and medicated individuals with schizophrenia show impairments across a wide array of cognitive and reinforcement learning tasks. 2020 , 1-11	4
407	Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated. 2020 , 23, 799-810	5
406	A MEG Study of Visual Repetition Priming in Schizophrenia: Evidence for Impaired High-Frequency Oscillations and Event-Related Fields in Thalamo-Occipital Cortices. 2020 , 11, 561973	1
405	Heritability of Memory Functions and Related Brain Volumes: A Schizophrenia Spectrum Study of 214 Twins. 2020 , 1,	2
404	Polygenic scores for schizophrenia and general cognitive ability: associations with six cognitive domains, premorbid intelligence, and cognitive composite score in individuals with a psychotic disorder and in healthy controls. 2020 , 10, 416	5
403	Raloxifene augmentation in men and women with a schizophrenia spectrum disorder: A study protocol. 2020 , 20, 100681	3
402	Catechol-O-methyltransferase genotype differentially contributes to the flexibility and stability of cognitive sets in patients with psychotic disorders and their first-degree relatives. <i>Schizophrenia Research</i> , 2020 , 223, 236-241	3.6 1
401	Symptomatic remission affects employment outcomes in schizophrenia patients. 2020 , 20, 219	1
400	Anti-PDHA1 antibody is detected in a subset of patients with schizophrenia. 2020 , 10, 7906	0
399	Focusing on recovery goals improves motivation in first-episode psychosis. 2020 , 55, 1629-1637	7

398	Neuropsychological features in patients with severe mental disorders and risk of violence: A prospective multicenter study in Italy. 2020 , 289, 113027		3
397	Chronic fatigue and fibromyalgia symptoms are key components of deficit schizophrenia and are strongly associated with activated immune-inflammatory pathways. <i>Schizophrenia Research</i> , 2020 , 222, 342-353	3.6	5
396	Translating ENIGMA schizophrenia findings using the regional vulnerability index: Association with cognition, symptoms, and disease trajectory. 2020 ,		6
395	The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis. 2020 , 291, 113246		8
394	Do neurobiological differences exist between paranoid and non-paranoid schizophrenia? Findings from the bipolar schizophrenia network on intermediate phenotypes study. <i>Schizophrenia Research</i> , 2020 , 223, 96-104	3.6	1
393	Increased Plasma Level of Longevity Protein Klotho as a Potential Indicator of Cognitive Function Preservation in Patients With Schizophrenia. 2020 , 14, 610		3
392	Tobacco smoking, related harm and motivation to quit smoking in people with schizophrenia spectrum disorders. 2020 , 8, 9042		5
391	Prednisolone versus placebo addition in the treatment of patients with recent-onset psychotic disorder: a trial design. 2020 , 21, 492		2
390	Effect of body anthropometrics on brain structure of offspring of parents with bipolar disorder. 2020 , 124, 137-142		1
389	Retinal layer abnormalities and their association with clinical and brain measures in psychotic disorders: A preliminary study. 2020 , 299, 111061		10
388	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2020 , 218, 48-54	3.6	4
387	Plasticity of DNA methylation, functional brain connectivity and efficiency in cognitive remediation for schizophrenia. 2020 , 126, 122-133		2
386	Modelling of self-management in schizophrenia: The role of neurocognition, self-efficacy and motivation. 2020 , 29, 3966-3976		4
385	Aerobic exercise and cognitive functioning in schizophrenia: Results of a 1-year follow-up from a randomized controlled trial. 2020 , 286, 112854		5
384	To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. 2020 , 21, 147		14
383	Cross-cultural comparison of theory of mind deficits in patients with schizophrenia from China and Denmark: different aspects of ToM show different results. 2020 , 74, 366-373		3
382	Measurement based care in schizophrenia-Feasibility in routine clinical practice. 2020 , 49, 101954		3
381	Reduced White Matter Integrity and Deficits in Neuropsychological Functioning in Adults With Autism Spectrum Disorder. 2020 , 13, 702-714		7

380	Cognitive risk factors for psychosis. 2020 , 269-287		0
379	Negative and disorganized symptoms mediate the relationship between verbal learning and global functioning in adolescents with early-onset psychosis. 2020 , 29, 1693-1703		3
378	Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model. 2020 , 33, 158-163		5
377	Design and validation of a brief scale for cognitive evaluation in people with a diagnosis of schizophrenia (BCog-S). 2020 , 27, 543-552		1
376	Experiential negative symptoms are more predictive of real-life functional outcome than expressive negative symptoms in clinical high-risk states. <i>Schizophrenia Research</i> , 2020 , 218, 151-156	3.6	7
375	Defining cognitive and functional profiles in schizophrenia and affective disorders. 2020 , 20, 39		10
374	The cognitive footprint of medication: A review of cognitive assessments in clinical trials. 2020 , 45, 874-880		1
373	Association of Magnetoencephalographically Measured High-Frequency Oscillations in Visual Cortex With Circuit Dysfunctions in Local and Large-scale Networks During Emerging Psychosis. 2020 , 77, 852-862		15
372	Associations between facial affect recognition and neurocognition in subjects at ultra-high risk for psychosis: A case-control study. 2020 , 290, 112969		2
371	Cognitive impairment in methamphetamine users with recent psychosis: A cross-sectional study in Thailand. 2020 , 210, 107961		3
370	Feasibility and acceptability of cognitive rehabilitation during the acute phase of schizophrenia. 2021 , 15, 457-462		3
369	Persistent negative symptoms in youth at clinical high risk for psychosis: A longitudinal study. <i>Schizophrenia Research</i> , 2021 , 227, 28-37	3.6	8
368	Childhood trauma and cognitive functioning in individuals at clinical high risk (CHR) for psychosis. 2021 , 33, 53-64		3
367	Altered cerebral perfusion in bipolar disorder: A pCASL MRI study. 2021 , 23, 130-140		3
366	Neural Oscillatory Abnormalities During Gaze Processing in Schizophrenia: Evidence of Reduced Theta Phase Consistency and Inter-areal Theta-Gamma Coupling. 2021 , 6, 370-379		3
365	Evaluation of cognitive impairment in a French sample of patients with restrictive anorexia nervosa: two distinct profiles emerged with differences in impaired functions and psychopathological symptoms. 2021 , 26, 1559-1570		2
364	A White Matter Connection of Schizophrenia and Alzheimer's Disease. 2021 , 47, 197-206		11
363	Neuropsychological deficits correlate with symptoms severity and cortical thickness in Borderline Personality Disorder. 2021 , 278, 181-188		0

362	The Computerized Functional Skills Assessment and Training Program: Sensitivity to Global Cognitive Impairment, Correlations With Cognitive Abilities, and Factor Structure. 2021 , 29, 395-404	0
361	Mental Health in Patients With Adrenal Incidentalomas: Is There a Relation With Different Degrees of Cortisol Secretion?. 2021 , 106, e130-e139	3
360	Cognitive decline and impairment in schizophrenia spectrum disorders reconsidered. <i>Schizophrenia Research</i> , 2021 , 228, 626-632	3.6 3
359	White matter microstructure across brain-based biotypes for psychosis - findings from the bipolar-schizophrenia network for intermediate phenotypes. 2021 , 308, 111234	4
358	Socioeconomic status and the effectiveness of treatment for first-episode psychosis. 2021 , 56, 409-417	2
357	Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis. 2021 , 47, 712-721	3
356	Attention bias modification in depression: A randomized trial using a novel, reward-based, eye-tracking approach. 2021 , 71, 101621	2
355	High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments. 2021 , 47, 530-541	8
354	Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates. 2021 , 36, 169-183	6
353	Non-Invasive Brain Stimulation Does Not Improve Working Memory in Schizophrenia: A Meta-Analysis of Randomised Controlled Trials. 2021 , 31, 115-138	7
352	 2021 , 205-210	
351	Exploring Movement Impairments in Patients With Parkinson's Disease Using the Microsoft Kinect Sensor: A Feasibility Study. 2020 , 11, 610614	2
350	Generalized neurocognitive impairment in individuals at ultra-high risk for psychosis: The possible key role of slowed processing speed. 2021 , 11, e01962	3
349	Computerized Assessment of Psychosis Risk. 2021 , 6,	0
348	Ecological momentary facial emotion recognition in psychotic disorders. 2021 , 1-9	4
347	Long range temporal correlations (LRTCs) in MEG-data during emerging psychosis: Relationship to symptoms, medication-status and clinical trajectory. 2021 , 31, 102722	1
346	Neurocognitive Deficits Mediate the Relationship Between Structural Abnormalities and Clinical Outcomes in Individuals With Ultrahigh Risk for Psychosis: A Multimodal Neuroimaging and Longitudinal Neurocognitive Study. 2021 , 2,	1
345	Evaluating the feasibility of a decision aid to promote shared decision making among young adults with first-episode psychosis: protocol for a pilot study. 2021 , 7, 22	3

344	Potential contribution of pineal atrophy and pineal cysts toward vulnerability and clinical characteristics of psychosis. 2021 , 32, 102805		2
343	UP'S: A Cohort Study on Recovery in Psychotic Disorder Patients: Design Protocol. 2020 , 11, 609530		0
342	Effectiveness of Metacognitive Training for Long-Term Hospitalized Patients with Schizophrenia: A Pilot Study with a Crossover Design. 2021 , 17, 45-52		2
341	White Matter in Prolonged Glucocorticoid Response to Psychological Stress in Schizophrenia.		
340	Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation with cognitive functioning.		
339	Facilitative Effects of Transcranial Direct Current Stimulation on Semantic Memory Examined by Text-Mining Analysis in Patients With Schizophrenia. 2021 , 12, 583027		0
338	Symptomatology and neurocognition among first-episode psychosis patients with and without cannabis use in the three months prior to first hospitalization. <i>Schizophrenia Research</i> , 2021 , 228, 83-88	3.6	3
337	Forecasting Remission From the Psychosis Risk Syndrome With Mismatch Negativity and P300: Potentials and Pitfalls. 2021 , 6, 178-187		1
336	Effects of aerobic walking on cognitive function in patients with schizophrenia: A randomized controlled trial. 2021 , 134, 173-180		2
335	In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy. 2021 , 36, 939-955		3
334	Performance on the Wechsler Adult Intelligence Scale (WAIS) in Japanese patients with bipolar and major depressive disorders in euthymic and depressed states. 2021 , 75, 128-137		1
333	Where do we cut the bell-shaped curve of CIAS?. <i>Schizophrenia Research</i> , 2021 , 228, 633-634	3.6	1
332	Suicidal ideation in first-episode psychosis: Considerations for depression, positive symptoms, clinical insight, and cognition. <i>Schizophrenia Research</i> , 2021 , 228, 298-304	3.6	3
331	Sex-Specific Associations of Polymorphisms With Schizophrenia in a Han Chinese Cohort. 2021 , 12, 627874		1
330	Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial. 2021 , 47, 1108-1115		3
329	Antisaccade error rates and gap effects in psychosis syndromes from bipolar-schizophrenia network for intermediate phenotypes 2 (B-SNIP2). 2021 , 1-10		1
328	Predicting Real-World Functioning in Schizophrenia: The Relative Contributions of Neurocognition, Functional Capacity, and Negative Symptoms. 2021 , 12, 639536		2
327	Reduced white matter microstructure in bipolar disorder with and without psychosis. 2021 ,		2

326	Combining compensatory cognitive training and medication self-management skills training, in inpatients with schizophrenia: A three-arm parallel, single-blind, randomized controlled trial. 2021 , 69, 94-103		0
325	Reduced Hippocampal Subfield Volume in Schizophrenia and Clinical High-Risk State for Psychosis. 2021 , 12, 642048		1
324	Smoking Is Related to Reduced Motivation, But Not Global Cognition, in the First Two Years of Treatment for First Episode Psychosis. 2021 , 10,		3
323	Investigating potential associations between neurocognition/social cognition and oxidative stress in schizophrenia. 2021 , 298, 113832		2
322	Usefulness of a psychomotor function test as a cognitive function scale for patients with schizophrenia: A pilot study. 2021 , 7, e06719		
321	White matter brain aging in relationship to schizophrenia and its cognitive deficit. <i>Schizophrenia Research</i> , 2021 , 230, 9-16	3.6	4
320	Prolonged P300 Latency in Antipsychotic-Free Subjects with At-Risk Mental States Who Later Developed Schizophrenia. 2021 , 11,		2
319	Heschl's Gyrus Duplication Pattern in Individuals at Risk of Developing Psychosis and Patients With Schizophrenia. 2021 , 15, 647069		1
318	Association of neurocognitive functioning with sleep stage dissociation and REM sleep instability in medicated patients with schizophrenia. 2021 , 136, 198-203		1
317	Lowered serum cesium levels in schizophrenia: association with immune-inflammatory biomarkers and cognitive impairments. 2021 , 43, 131-137		2
316	Cannabidiol and Amisulpride Improve Cognition in Acute Schizophrenia in an Explorative, Double-Blind, Active-Controlled, Randomized Clinical Trial. 2021 , 12, 614811		5
315	Neurocognitive profiles of patients with first-episode and recurrent depression: a cross-sectional comparative study from China. 2021 , 286, 110-116		0
314	Anomalous self-experiences in cognition are negatively associated with neurocognitive functioning in schizophrenia. 2021 , 26, 307-320		0
313	Neurological and cognitive sequelae of Covid-19: a four month follow-up. 2021 , 268, 4422-4428		23
312	The relationship between cognitive deficits and impaired short-term functional outcome in clinical high-risk for psychosis participants: A machine learning and modelling approach. <i>Schizophrenia Research</i> , 2021 , 231, 24-31	3.6	3
311	In schizophrenia, immune-inflammatory pathways are strongly associated with depressive and anxiety symptoms, which are part of a latent trait which comprises neurocognitive impairments and schizophrenia symptoms. 2021 , 287, 316-326		6
310	Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. 2021 , 94, 138-147		88
309	Predictors of work and education among people with severe mental illness who participated in the Danish individual placement and support study: findings from a randomized clinical trial. 2021 , 56, 1669-1677		0

308	Cross-cultural adaptation and validation of the Arabic version of the BACS scale (the brief assessment of cognition in schizophrenia) among chronic schizophrenic inpatients. 2021 , 21, 223	5
307	Schizophrenia and spp. Infection: A Pilot Case-Control Study. 2021 , 21, 413-421	3
306	Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. 2021 , 46, 1802-1810	3
305	Cannabinoid receptor gene polymorphisms and cognitive performance in patients with schizophrenia and controls. 2021 ,	2
304	Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder. 2021 , 41, 501-503	0
303	Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7 T. 2021 , 11, 367	4
302	Disentangling Cognitive Heterogeneity in Psychotic Spectrum Disorders. 2021 , 60, 102651	
301	Executive Dysfunctions in Schizophrenia: A Critical Review of Traditional, Ecological, and Virtual Reality Assessments. 2021 , 10,	2
300	Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. 2021 , 46, 2320-2329	2
299	Associations between cognition and white matter microstructure in first-episode antipsychotic-naïve patients with schizophrenia and healthy controls: A multivariate pattern analysis. 2021 , 139, 282-297	1
298	Assessing cognition in people with severe mental disorders in low- and middle-income countries: a systematic review of assessment measures. 2021 , 1	1
297	Multisensory Processing Can Compensate for Top-Down Attention Deficits in Schizophrenia. 2021 , 31, 5536-5548	1
296	Forma corta de cuatro subtest de la WAIS-IV para la evaluación de pacientes con diagnóstico de esquizofrenia. 2021 , 14, 139-147	
295	Mapping brain-behavior space relationships along the psychosis spectrum. 2021 , 10,	2
294	The Impact of Negative Symptoms and Neurocognition on Functioning in MDD and Schizophrenia. 2021 , 12, 648108	3
293	Cognitive Impairments in Schizophrenia: A Study in a Large Clinical Sample Using Natural Language Processing. 2021 , 3, 711941	1
292	The effect of antipsychotics on the cognitive performance of individuals with psychotic disorders: Network meta-analyses of randomized controlled trials. 2021 , 126, 265-275	9
291	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. 2021 , 90, 632-642	8

290	White matter in prolonged glucocorticoid response to psychological stress in schizophrenia. 2021 , 46, 2312-2319	1
289	Four-subtest short-form of the WAIS-IV for assessment of patients diagnosed with schizophrenia. 2021 , 14, 139-147	
288	Insight Into Illness and Psychological Defense Attitudes in People With Chronic Schizophrenia Using Markova's Insight Scale. 2021 , 209, 879-883	
287	Duration of basic and attenuated-psychotic symptoms in individuals at clinical high risk for psychosis: pattern of symptom onset and effects of duration on functioning and cognition. 2021 , 21, 339	1
286	A Diagnosis and Biotype Comparison Across the Psychosis Spectrum: Investigating Volume and Shape Amygdala-Hippocampal Differences from the B-SNIP Study. 2021 , 47, 1706-1717	1
285	Aerobic exercise and cognitive functioning in schizophrenia: Findings of dose-response analysis from a pilot randomized controlled trial. <i>Schizophrenia Research</i> , 2021 ,	3.6
284	Study Protocol: The Evaluation Study for Social Cognition Measures in Japan (ESCoM). 2021 , 11,	2
283	Characterising cognitive heterogeneity in individuals at clinical high-risk for psychosis: a cluster analysis with clinical and functional outcome prediction. 2021 , 1	2
282	Psychosis Biotypes: Replication and Validation from the B-SNIP Consortium. 2021 ,	1
281	Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial. 2021 , 21, 404	1
280	The relationship between sleep disturbance and cognitive impairment in mood disorders: A systematic review.	
279	Circulating inflammatory markers impact cognitive functions in bipolar depression. 2021 , 140, 110-116	4
278	Acoustic speech markers for schizophrenia-spectrum disorders: a diagnostic and symptom-recognition tool. 2021 , 1-11	0
277	Longitudinal Improvement of Neurocognition after Electroconvulsive Therapy in Bipolar Depression. 2021 , 2021, 7748073	
276	General description of cognitive deficits in schizophrenia and assessment tools in Lebanon: A scoping review. 2021 , 25, 100199	0
275	Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals. 2021 , 1	1
274	A multinational case-control study comparing forensic and non-forensic patients with schizophrenia spectrum disorders: the EU-VIORMED project. 2021 , 1-11	3
273	Quantifying Retinal Microvascular Morphology in Schizophrenia Using Swept-Source Optical Coherence Tomography Angiography. 2021 ,	3

272	Southwestern Assessment of Processing Speed (SWAPS): A new brief test with demographically-corrected norms in an ethnically and educationally diverse population. 2021 , 1-18		0
271	Sleep Disturbance in Individuals at Clinical High Risk for Psychosis. 2021 ,		3
270	Screening for cognitive impairment in schizophrenia: Psychometric properties of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G). 2021 , 25, 100197		2
269	Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?. 2021 , 141, 346-352		4
268	40-Hz Auditory Steady-State Responses Characterize Circuit Dysfunctions and Predict Clinical Outcomes in Clinical High-Risk for Psychosis Participants: A Magnetoencephalography Study. 2021 , 90, 419-429		11
267	Immunological investigations of the cerebrospinal fluid in patients with recent onset psychotic disorders: A study protocol. 2021 , 16, e0257946		1
266	Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial. <i>Schizophrenia Research</i> , 2021 , 235, 44-51	3.6	1
265	Subtypes of schizophrenia identified by multi-omic measures associated with dysregulated immune function. 2021 ,		3
264	Auditory Oddball Responses Across the Schizophrenia-Bipolar Spectrum and Their Relationship to Cognitive and Clinical Features. 2021 , 178, 952-964		2
263	The effects of JNJ-39393406 a positive allosteric nicotine modulator on mood and cognition in patients with unipolar depression: A double-blind, add-on, placebo-controlled trial. 2021 , 51, 33-42		2
262	Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. <i>Schizophrenia Research</i> , 2021 , 236, 54-60	3.6	0
261	Inflammatory cytokines, cognition, and response to antidepressant treatment in patients with major depressive disorder. 2021 , 305, 114202		1
260	Cognitive discrepancies, motivation and subjective well-being in people with schizophrenia. 2021 , 26, 100205		1
259	Assessing methamphetamine-related cue reactivity in people with methamphetamine use disorder relative to controls. 2021 , 123, 107075		2
258	Inter-device reliability of swept source and spectral domain optical coherence tomography and retinal layer differences in schizophrenia. 2021 , 5, 100036		1
257	Anterior-posterior axis of hippocampal subfields across psychoses: A B-SNIP study. 2021 , 5, 100037		0
256	Stressful life events and openness to experience: Relevance to depression. 2021 , 295, 711-716		2
255	Self-assessment of social cognition in a sample of Lebanese in-patients with schizophrenia. 2021 , 26, 100207		2

254	Cognitive impairments in schizophrenia in foreign studies: single function deficits or group of syndromes?. 2021 , 10, 8-19		0
253	The clinical characterization of the patient with primary psychosis aimed at personalization of management. 2021 , 20, 4-33		43
252	Neurocognitive Impairments in Schizophrenia: Their Character and Role in Symptom Formation. 142-162		2
251	Cannabis-Induced Psychosis. 2019 , 115-135		1
250	Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia. 2011 , 33-74		1
249	How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review. 2019 , 269, 87-105		44
248	The influence of negative and affective symptoms on anhedonia self-report in schizophrenia. 2020 , 98, 152165		3
247	Thalamic and striato-pallidal volumes in schizophrenia patients and individuals at risk for psychosis: A multi-atlas segmentation study. <i>Schizophrenia Research</i> , 2020 ,	3.6	6
246	Alterations in facial expressivity in youth at clinical high-risk for psychosis. 2019 , 128, 341-351		16
245	Factor structure of cognition and functional capacity in two studies of schizophrenia and bipolar disorder: Implications for genomic studies. 2016 , 30, 28-39		25
244	An exploration of linear and curvilinear relationships between community participation and neurocognition among those with serious mental illnesses. 2019 , 42, 358-365		4
243	Communication in schizophrenia, between pragmatics, cognition, and social cognition. 213-234		5
242	Features of Duration Mismatch Negativity Around the Onset of Overt Psychotic Disorders: A Longitudinal Study. 2021 , 31, 2416-2424		4
241	Evaluation of a Novel Technology-Based Program Designed to Assess and Train Everyday Skills in Older Adults. 2020 , 4, igaa052		5
240	Remote Ecological Momentary Testing of Learning and Memory in Adults With Serious Mental Illness. 2021 , 47, 740-750		6
239	Cognitive Remediation for Inpatients With Schizophrenia: Effects of a Brief and Intensive Training. 2021 , 209, 76-81		1
238	Higher genetic risk of schizophrenia is associated with lower cognitive performance in healthy individuals.		3
237	Schizophrenia Exhibits Bi-Directional Brain-Wide Alterations in Cortico-Striato-Cerebellar Circuits.		1

236	A 12-month randomised, double-blind, controlled, multicentre trial comparing changes in Cigarette consumption after switchinG to high or low nicotine strENght E-cigaretteS In smokers with Schizophrenia spectrum disorders: Protocol for the GENESIS Trial.	1
235	Prevalence and predictors of suicidality and non-suicidal self-harm among individuals at clinical high-risk for psychosis: Results from a community-recruited sample. 2021 , 15, 1256-1265	2
234	Association of typical versus atypical antipsychotics with symptoms and quality of life in schizophrenia. 2012 , 7, e37087	18
233	Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. 2012 , 7, e42676	187
232	Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state. 2013 , 8, e54080	69
231	Subjective cognitive complaints in schizophrenia: relation to antipsychotic medication dose, actual cognitive performance, insight and symptoms. 2013 , 8, e83774	23
230	Neuropsychological Impairment and Its Association with Violence Risk in Japanese Forensic Psychiatric Patients: A Case-Control Study. 2016 , 11, e0148354	10
229	Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia. 2016 , 11, e0155631	45
228	Patients with schizophrenia activate behavioural intentions facilitated by counterfactual reasoning. 2017 , 12, e0178860	2
227	Whole-Brain Source-Reconstructed MEG-Data Reveal Reduced Long-Range Synchronization in Chronic Schizophrenia. 2017 , 4,	22
226	[Network analysis of cognitive, oculomotor and speech parameters in schizophrenia]. 2020 , 120, 54-60	3
225	Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. 2014 , 20, 5077-92	22
224	Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia. 2020 , 20, 747-758	12
223	Evidence for an immune role on cognition in schizophrenia: a systematic review. 2014 , 12, 273-80	55
222	New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function. 2015 , 13, 793-801	13
221	Pilot Study of the Effects of Cognitive Remediation Therapy Using the Frontal/Executive Program for Treating Chronic Schizophrenia. 2016 , 09, 121-128	1
220	The Ubiquitous Cognitive Assessment Tool for Smartwatches: Design, Implementation, and Evaluation Study. 2020 , 8, e17506	5
219	Cognitive training in virtual reality vs. cogpack in patients with schizophrenia: study proposal. 2020 , 61,	1

218	Reduced Temporal Activation During a Verbal Fluency Task is Associated with Poor Motor Speed in Patients with Major Depressive Disorder. 2020 , 17, 804-813	3
217	The assessment of neuropsychological functioning in schizophrenia. 2010 , 12, 383-92	156
216	Domains of cognition and their assessment?. 2019 , 21, 227-237	85
215	Comparing Copper Serum Level and Cognitive Functioning in Patients With Schizophrenia and Healthy Controls. 2020 , 11, 649-657	1
214	Psychological approaches to understanding and promoting recovery in psychosis and bipolar disorder: a mixed-methods approach. 2016 , 4, 1-272	11
213	Deconstructing Schizophrenia for DSM-V: Challenges for Clinical and Research Agendas. 2008 , 2, 166-174	15
212	Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. 2011 , 5, 17-25	23
211	Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications. 2018 , 80,	3
210	Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. 2013 , 15,	2
209	Neuropsychiatric screening in type 2 diabetes mellitus. 2012 , 16 Suppl 1, S37-40	5
208	French Validation of the Screen for Cognitive Impairment in Psychiatry (SCIP-F). 2016 , 06, 107-118	7
207	Introduction of Music Therapy Incorporated into Cognitive Remediation: A New Approach to Cognitive Dysfunction in Psychiatric Disorders and a Preliminary Report on Its Effects in Schizophrenia. 2019 , 09, 23-38	2
206	Working Memory in Patients with Major Depressive Disorder. 2012 , 03, 758-761	2
205	Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia). 2015 , 70, 278-82	9
204	Resting-state gamma-band power alterations in schizophrenia reveal E/I-balance abnormalities across illness-stages. 2018 , 7,	50
203	Defining cognitive profiles of depressive patients using the Brief Assessment of Cognition in Affective Disorders. 2019 , 7, e7432	8
202	The Assessment of Executive Functions: A New Neuropsychological Tool for Addiction. 2021 , 61-85	0
201	Cerebral and behavioral signs of impaired cognitive flexibility and stability in schizophrenia spectrum disorders. 2021 , 32, 102855	0

- 200 Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: role of depression and impact on quality of life. **2021**, 1 7
- 199 Causal pathways to social and occupational functioning in the first episode of schizophrenia: uncovering unmet treatment needs. 1-9 0
- 198 The screen for cognitive impairment in psychiatry (SCIP) as a routinely applied screening tool: pathology of acute psychiatric inpatients and cluster analysis. **2021**, 21, 494 0
- 197 Early evoked brain activity underlies auditory and audiovisual speech recognition deficits in schizophrenia.
- 196 Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis. **2021**, 1-11 3
- 195 Avaliaç o neuropsicol gica na esquizofrenia: revis o sistem tica. **2008**, 30,
- 194 Z-Score. **2010**, 1433-1435
- 193 Cognition. **2012**, 15-31
- 192 Valutazioni del funzionamento cognitivo trasferibili alla pratica clinica: le scale BACS e SCORS. **2013**, 59-68
- 191 L'assessment neuropsicologico nella schizofrenia. **2013**, 49-58
- 190 Reliability and Validity of the Malay Version of the Brief Assessment of Cognition in Schizophrenia (BACS): Preliminary Results. **2013**, 5, 235-244
- 189 A Multidisciplinary First-Episode Psychosis Program. **2015**, 45, 561-568
- 188 Clinical Correlates Associated with Basic Ability of Social Life in Schizophrenia Inpatients. **2016**, 06, 71-75
- 187 Schizophrenia. **2016**, 91-120 2
- 186 Cognitive Enhancement in the Early Phases of Psychosis. **2019**, 259-276
- 185 COGNITIVE DETERMINANTS OF REAL WORLD SOCIAL FUNCTIONING IN FIRST EPISODE SCHIZOPHRENIA. **2018**, 5, 2752-2759
- 184 Cognitive Enhancement in Schizophrenia and Related Disorders. **2019**, 1
- 183 Cortico-thalamic dysconnectivity links with aberrant striatal dopamine in schizophreniaA simultaneous 18F-DOPA-PET/resting-state fMRI study.

182	Cost-Effectiveness of Individualized Occupational Therapy for Schizophrenia: Results from a Two-Year Randomized Controlled Trial. 2020 , 16, 29-34	
181	Multisensory processes can compensate for attention deficits in schizophrenia.	
180	Corticolimbic brain anomalies are associated with cognitive subtypes in psychosis: A longitudinal study. 2020 , 63, e40	2
179	[The relationship of psychosocial well-being of patients with schizophrenia with clinical, socio-demographic and neurocognitive characteristics]. 2020 , 120, 105-112	
178	Subjectively-assessed cognitive impairment and neurocognition associations in schizophrenia inpatients. 2022 , 27, 100218	
177	Outcome Measurement in Schizophrenia: Challenges and Barriers. 2020 , 91-124	0
176	Neurocognitive impairments in patients with schizophrenia and schizophrenia spectrum disorders: cluster analysis results. 2020 , 45-51	3
175	White matter brain aging In Relationship to Schizophrenia and Its Cognitive Deficit.	
174	The metacognitive functioning of patients with paranoid schizophrenia through the prism of emotional intelligence: a connection with cognitive deficit, clinical manifestations, social functioning and quality of life. 2020 , 73-82	
173	Mapping Brain-Behavior Space Relationships Along the Psychosis Spectrum.	0
172	40 Hz Auditory Steady-State Responses Predict Transition to Psychosis in Clinical-High-Risk Participants: A MEG Study.	
171	Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. 2006 , 31, 369-76	29
170	The effectiveness of computerized cognitive rehabilitation training program in improving cognitive abilities of schizophrenia clients. 2014 , 9, 209-15	3
169	Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. 2011 , 44, 18-31	33
168	Age at Onset and Social Cognitive Impairment in Clinically Stabilized Patients with Schizophrenia: An Ecological Cross-Sectional Study. 2018 , 13, 84-93	3
167	Research Status and Strategies for Cognitive Function in Schizophrenia. 2018 , 30, 199-201	
166	Evaluating the utility of digital phenotyping to predict health outcomes in schizophrenia: protocol for the HOPE-S observational study. 2021 , 11, e046552	2
165	Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. 2021 , 11, e054160	0

164	The Implementation and Review of Cognitive Remediation Training for First Episode Psychosis in Singapore.. 2021 , 12, 784935		0
163	Improvements in Cognitive Performance With Computerized Training in Older People With and Without Cognitive Impairment: Synergistic Effects of Skills-Focused and Cognitive-Focused Strategies.. 2021 ,		0
162	Neurologic and cognitive sequelae after SARS-CoV2 infection: Different impairment for ICU patients. 2021 , 432, 120061		4
161	Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients.. 2021 , 12, 777378		0
160	Surface area in the insula was associated with 28-month functional outcome in first-episode psychosis. 2021 , 7, 56		0
159	Minor hallucinations in isolated rapid eye movement sleep behavior disorder indicative of early phenoconversion: A preliminary study. 2021 ,		0
158	Comparison of Black and White participants with severe mental illness in response to cognitive remediation as an augmentation of vocational rehabilitation. <i>Schizophrenia Research</i> , 2021 ,	3.6	0
157	Subjective cognitive complaints and relations to objective cognitive performance among Lebanese patients with schizophrenia. 2021 , 21, 549		0
156	Negative Symptom Domains Are Associated With Verbal Learning in Adolescents With Early Onset Psychosis.. 2021 , 12, 825681		2
155	Early evoked brain activity underlies auditory and audiovisual speech recognition deficits in schizophrenia.. 2021 , 33, 102909		1
154	Effect of antipsychotic dose reduction on cognitive function in schizophrenia.. 2022 , 308, 114383		0
153	Clinical insight and cognitive functioning as mediators in the relationships between symptoms of psychosis, depression, and suicide ideation in first-episode psychosis.. 2022 , 147, 85-93		0
152	Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients. 2021 , 114, 110493		0
151	Multimodal Dataset of Social Skills Training in Natural Conversational Setting. 2021 ,		0
150	Real-time facial emotion recognition deficits across the psychosis spectrum: A B-SNIP Study. <i>Schizophrenia Research</i> , 2021 ,	3.6	
149	Neuroimmunological investigations of cerebrospinal fluid in patients with recent onset depression - a study protocol.. 2022 , 22, 35		1
148	An examination of neurocognition and theory of mind as predictors of engagement with a tailored digital therapeutic in persons with serious mental illness.. 2022 , 28, 100236		
147	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. 2022 , 3,		0

146	Relationships between global functioning and neuropsychological predictors in subjects at high risk of psychosis or with a recent onset of depression.. 2022 , 1-9		0
145	It is time to address language disorders in schizophrenia: A RCT on the efficacy of a novel training targeting the pragmatics of communication (PragmaCom).. 2022 , 97, 106196		1
144	Impact of cognitive remediation on the prediction of employment outcomes in severe mental illness.. <i>Schizophrenia Research</i> , 2022 , 241, 149-155	3.6	0
143	Semantic and phonetic similarity of verbal fluency responses in early-stage psychosis.. 2022 , 309, 114404		1
142	Web-Based Cognitive Testing in Psychiatric Research: Validation and Usability Study.. 2022 , 24, e28233		1
141	The use of the Montreal Cognitive Assessment (MoCA) screening tool to evaluate cognitive deficits in Lebanese in-patients with schizophrenia.. 2022 , 70, 103029		0
140	Alteration of gut microbiome in patients with schizophrenia indicates links between bacterial tyrosine biosynthesis and cognitive dysfunction. 2022 ,		2
139	A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia.. 2021 , 46, E675-E701		2
138	Web-Based Cognitive Testing in Psychiatric Research: Validation and Usability Study (Preprint).		
137	The Association Between Executive Functioning and Personal Recovery in People With Psychotic Disorders. 2022 , 3,		0
136	The interleukin-6/interleukin-23/Thelper-17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: a precision nomothetic psychiatry analysis.		0
135	Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning.. 2022 , 2698811221077199		0
134	Brief battery of the Social Cognition Psychometric Evaluation study (BB-SCOPE): Development and validation in schizophrenia spectrum disorders.. 2022 , 150, 307-316		1
133	MR-Spectroscopy of GABA and Glutamate/Glutamine Concentrations in Auditory Cortex in Clinical High-Risk for Psychosis Individuals.. 2022 , 13, 859322		
132	The neurobiological characterization of distinct cognitive subtypes in early-phase schizophrenia-spectrum disorders.. <i>Schizophrenia Research</i> , 2022 , 241, 228-237	3.6	0
131	A subtype of institutionalized patients with schizophrenia characterized by pronounced subcortical and cognitive deficits.. 2022 ,		0
130	Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses.. 2022 , 13, 834333		1
129	Wirkungen von Cariprazin auf Negativsymptome und kognitive Störungen bei Schizophrenie. 1		0

128	Inflammation subtypes in psychosis and their relationships with genetic risk for psychiatric and cardiometabolic disorders.. 2022 , 22, 100459	0
127	Cognitive remediation in schizophrenia: What happens after 10 years?. 2022 , 29, 100251	1
126	Validation of an ecological momentary assessment to measure processing speed and executive function in schizophrenia.. 2021 , 7, 64	2
125	Distinct neuroanatomic subtypes in antipsychotic-treated patients with schizophrenia classified by the predefined classification in a never-treated sample. 2021 , 1, 212-224	
124	Neurocognition and social cognition in patients with schizophrenia spectrum disorders with and without a history of violence: results of a multinational European study. 2021 , 11, 620	1
123	Translating RDoC to Real-World Impact in Developmental Psychopathology: A Neurodevelopmental Framework for Application of Mental Health Risk Calculators.. 2021 , 33, 1665-1684	2
122	Patterns of impaired neurocognitive performance on Global Neuropsychological Assessment (GNA), and their brain structural correlates in recent-onset and chronic schizophrenia: A pilot study.	
121	Sex Differences in Social Cognition and Association of Social Cognition and Neurocognition in Early Course Schizophrenia.. 2022 , 13, 867468	0
120	Multimodal Correlates of Cannabis Use among U.S. Veterans with Bipolar Disorder: An Integrated Study of Clinical, Cognitive, and Functional Outcomes.. 2022 , 1-11	
119	Neuroinflammatory biomarkers in the cerebrospinal fluid from 106 patients with recent onset depression compared to 106 individually matched healthy controls. 2022 ,	1
118	Efficacy of Metacognitive Training for Patients With Schizophrenia in Psychiatric Emergency Wards: A Pilot Randomized Controlled Trial.. 2022 , 13, 861102	
117	Effect of Probiotics on the Traumatic Brain Injury. 2022 , 3, 59-67	
116	Regional and Sex-specific Alterations in the Visual Cortex of Individuals with Psychosis Spectrum Disorders. 2022 ,	0
115	Computerised cognitive training during early-stage psychosis improves cognitive deficits and gamma-band oscillations: A pilot study.. <i>Schizophrenia Research</i> , 2022 , 243, 217-219	3.6
114	Table_1.DOC. 2020 ,	
113	Table_2.DOC. 2020 ,	
112	Table_3.DOC. 2020 ,	
111	Image_1.pdf. 2018 ,	

110 Table_1.XLSX. 2018,

109 Table_2.XLSX. 2018,

108 Table_1.docx. 2020,

107 Data_Sheet_1.docx. 2020,

106 Image_1.TIFF. 2020,

105 Image_2.TIFF. 2020,

104 Role of the gut microbiome in three major psychiatric disorders.. 2022, 1-21

1

103 In schizophrenia, the effects of the IL-6/IL-23/Th17 axis on health-related quality of life and disabilities are partly mediated by generalized cognitive decline and the symptomatome.

0

102 The Interplay between Vitamin D, Exposure of Anticholinergic Antipsychotics and Cognition in Schizophrenia. 2022, 10, 1096

1

101 Modifiable predictors of self-reported and performance-based functioning in individuals with schizophrenia-spectrum disorders and high levels of negative symptoms.. 2022, 151, 347-353

0

100 Depressive cognitive style relates to an individual trait of time perception in bipolar depression: A preliminary study. 2022, 9, 100363

99  2012, 5,

98 Cognitive remediation therapy for post-acute persistent cognitive deficits in COVID-19 survivors: A proof-of-concept study.. 2022, 1-18

0

97 Childhood Trauma And Cannabis Interactions In Affecting Psychosis Onset: Role Of The Anterior-Posterior Axis Of The Hippocampus and Differences In Cannabis Use Before or After Psychosis Onset.

96 Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis. *Schizophrenia Research*, 2022, 244, 58-65

3.6

95 Decision-making and risk-taking in forensic and non-forensic patients with schizophrenia spectrum disorders: A multicenter European study. 2022, 29, 100257

94 Brain Derived Neurotrophic Factor and Cognitive Dysfunction in the Schizophrenia-Bipolar Spectrum: A Systematic Review and Meta-Analysis. 2022, 13,

0

93 Validation of the Brazilian version of the Hinting Task and Facial Emotion Recognition Test (FERT-100) in patients with schizophrenia.

- 92 Visual Imagery Imitation Skills and Cognitive Functions in Patients with Schizophrenia. 156918612211027 ○
- 91 Schizophrenia Spectrum and Other Psychotic Disorders. **2022**,
- 90 Hippocampal structural alterations in Early-Stage Psychosis: Specificity and Relationship to Clinical Outcomes. **2022**, 103087 ○
- 89 Transcranial Direct Current Stimulation on the Left Superior Temporal Sulcus Improves Social Cognition in Schizophrenia: An Open-Label Study. 13, ○
- 88 Linked brain connectivity patterns with psychopathological and cognitive phenotypes in drug-naïve first-episode schizophrenia. **2022**, 2, 43-51
- 87 Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study. **2022**, 8,
- 86 Cognitive Assessment in SARS-CoV-2 Patients: A Systematic Review. 14, 1
- 85 The Chinese Brief Cognitive Test: Normative Data Stratified by Gender, Age and Education. 13, ○
- 84 Montreal cognitive assessment (MoCA) and Digit symbol substitution test (DSST) as a screening tool for evaluation of cognitive deficits in schizophrenia. **2022**, 114731
- 83 The Italian version of the Brief Assessment of Cognition in Affective Disorders: performance of patients with bipolar disorder and healthy controls. **2022**, 117, 152335 ○
- 82 Dimensionality analysis of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G). **2022**, 29, 100259 ○
- 81 Global Examination of Mental State: An open tool for the brief evaluation of cognition. ○
- 80 Validation of the Chinese Version of the Schizophrenia Cognition Rating Scale. **2022**, 19, 511-518
- 79 A Pilot Study of Illness Management and Recovery in Patients Acutely Admitted to a Psychiatric Ward.
- 78 A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia. 13,
- 77 Negative symptoms, striatal dopamine, and model-free reward decision-making in schizophrenia.
- 76 Clinical efficacy and neurobiological correlates of electroconvulsive therapy in patients with clozapine-resistant/intolerant schizophrenia: study protocol of multi-site parallel arm double-blind randomized sham-controlled study. 7, 212
- 75 Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline. 13,

74	A neuropsychological approach to differentiating cannabis-induced and primary psychotic disorders.	
73	Cerebrospinal Fluid and Blood Biomarkers of Neuroinflammation and Blood-Brain Barrier in Psychotic Disorders and Individually Matched Healthy Controls.	0
72	Cognitive performances across individuals at high genetic risk for schizophrenia, high genetic risk for bipolar disorder, and low genetic risks: a combined polygenic risk score approach. 1-10	0
71	European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. 2022 , 65,	3
70	Brain-wide versus genome-wide vulnerability biomarkers for severe mental illnesses.	1
69	Unveiling the Associations between EEG Indices and Cognitive Deficits in Schizophrenia-Spectrum Disorders: A Systematic Review. 2022 , 12, 2193	2
68	Thalamocortical connectivity and its relationship with symptoms and cognition across the psychosis continuum. 1-10	0
67	Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial. 2022 , 8,	0
66	Neuropsychological Functioning and Suicidal Behaviours in Patients with First-Episode Psychosis: A Systematic Review.	0
65	Study protocol for evaluating the clinical efficacy and neurobiological correlates of sequential treatment with tDCS primed iTBS and ECT in treatment-resistant depression. 7, 242	0
64	Neurocognitive impairment in addiction: A digital tool for executive function assessment. 13,	0
63	Technology and Mental Health: State of the Art for Assessment and Treatment.	0
62	Clinical efficacy and neurobiological correlates of electroconvulsive therapy in patients with clozapine-resistant/intolerant schizophrenia: study protocol of multi-site parallel arm double-blind randomized sham-controlled study. 7, 212	0
61	Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach. 2022 , 155, 572-578	2
60	Behavioural phenotypes of intrinsic motivation in schizophrenia determined by cluster analysis of objectively quantified real-world performance. 2022 , 8,	0
59	Exploring the association between brain-derived neurotrophic factor (BDNF) levels and longitudinal psychopathological and cognitive changes in Sardinian psychotic patients. 1-19	0
58	The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis. 2022 , 17, e0275839	0
57	Anti-neuronal autoantibodies in the cerebrospinal fluid and serum from 106 patients with recent onset depression compared to 106 individually matched healthy controls. 2022 ,	0

- 56 Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis. **2022**, 12, ○
- 55 Effect of individualized occupational therapy on social functioning in patients with schizophrenia: A five-year follow-up of a randomized controlled trial. **2022**, ○
- 54 Understanding the relationship between apathy, cognition and functional outcome in schizophrenia: The significance of an ecological assessment. **2022**, 17, e0277047 ○
- 53 Smartphone digital phenotyping, surveys, and cognitive assessments for global mental health: Initial data and clinical correlations from an international first episode psychosis study. **2022**, 8, 205520762211337 ○
- 52 The α C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits. **2022**, 173490 ○
- 51 Identifying psychiatric manifestations in schizophrenia and depression from audio-visual behavioural indicators through a machine-learning approach. **2022**, 8, ○
- 50 Neuropsychological predictors of vocational rehabilitation outcomes in individuals with major depression: A scoping review. 13, ○
- 49 Cognitive reserve profiles are associated with outcome in schizophrenia.. **2022**, 120496 ○
- 48 Smoking Addiction in Patients with Schizophrenia Spectrum Disorders and Its Perception and Intervention in Healthcare Personnel Assigned to Psycho-Rehabilitation Programs: A Qualitative Research. **2022**, 10, 2275 1
- 47 Processing speed Δ a potential candidate cognitive endophenotype for bipolar disorder. **2023**, 11, 100459 ○
- 46 In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome. **2022**, 19, 15281 ○
- 45 Plasma neuropeptide levels in patients with schizophrenia, bipolar disorder, or major depressive disorder and healthy controls: A multiplex immunoassay study. 1
- 44 Deconstructing heterogeneity in schizophrenia through language: a semi-automated linguistic analysis and data-driven clustering approach. **2022**, 8, 1
- 43 Accelerated cortical thinning precedes and predicts conversion to psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk. ○
- 42 Effect of Virtual Reality on Cognitive Impairment and Clinical Symptoms among Patients with Schizophrenia in the Remission Stage: A Randomized Controlled Trial. **2022**, 12, 1572 1
- 41 Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study. **2022**, 12, e062570 ○
- 40 Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. **2022**, 400, 2210-2220 ○
- 39 Cognitive rehabilitation methods in multiple sclerosis patients. **2022**, 50, 321-328 ○

38	Multi-dimensional recording of long-term treatment of patients with schizophrenic disorders compared to patients with major depression measured with the ASSESS battery. 2022 , 8, e11924	0
37	Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia.	0
36	Cross-sectional associations between adaptive functioning and social cognitive and neurocognitive functions in adolescents with first-episode, early-onset schizophrenia spectrum disorders. 1-11	0
35	Lower fractional anisotropy without evidence for neuro-inflammation in patients with early-phase schizophrenia spectrum disorders. 2022 ,	0
34	Evidence supporting the use of a brief cognitive assessment in routine clinical assessment for psychosis. 2022 , 8,	0
33	Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders. 2022 , 12, 1666	1
32	A Diagnostic Perspective of Schizophrenia: From Past to Present. 2023 , 45-70	0
31	Dysfunctional Beliefs and Cognitive Performance across Symptom Dimensions in Childhood and Adolescent OCD. 2023 , 12, 219	0
30	Relapse prediction in schizophrenia with smartphone digital phenotyping during COVID-19: a prospective, three-site, two-country, longitudinal study. 2023 , 9,	0
29	Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia. 2023 , 23,	0
28	Impact of Cognitive Impairments on Health-Related Quality of Life in Schizophrenia. 2023 , 13, 215	1
27	Negative symptoms and cognitive impairment are associated with distinct motivational deficits in treatment resistant schizophrenia.	0
26	Characteristic association of symbol coding test score with occupational function in Japanese patients with schizophrenia.	0
25	Genetic variations in DOCK4 contribute to schizophrenia susceptibility in a Chinese cohort: A genetic neuroimaging study. 2023 , 443, 114353	0
24	Associations between saliva alpha-amylase, heart rate variability, saliva cortisol and cognitive performance in individuals at ultra high-risk for psychosis. 2023 , 255, 165-172	0
23	Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment.	1
22	Serum free thiols in recently diagnosed patients with schizophrenia spectrum disorder: A potentially useful biomarker of oxidative stress. 2023 , 321, 115075	0
21	Effects of exercise on cognitive functioning in adults with serious mental illness: A meta analytic review. 2023 , 321, 115081	0

- 20 Clustering of antipsychotic-naïve patients with schizophrenia based on functional connectivity from resting-state electroencephalography. ○
- 19 The relationship between sleep disturbance and cognitive impairment in mood disorders: A systematic review. **2023**, 327, 207-216 ○
- 18 Alteration of the Functional Connectivity of the Cortical Areas Characterized by the Presence of Von Economo Neurons in Schizophrenia, a Pilot Study. **2023**, 12, 1377 ○
- 17 Investigation of social and cognitive predictors in non-transition ultra-high-risk individuals for psychosis using spiking neural networks. **2023**, 9, ○
- 16 Faster bi-stable visual switching in psychosis. ○
- 15 Cross-Cultural Adaptation and Validation of the Serbian Version of the Brief Assessment of Cognition in Schizophrenia Scale. **2023**, 20, 3699 ○
- 14 Clinical Recovery and Long-Term Association of Specialized Early Intervention Services vs Treatment as Usual Among Individuals With First-Episode Schizophrenia Spectrum Disorder. **2023**, 80, 371 ○
- 13 Cognitive functioning in early-onset psychosis. **2023**, 127-152 ○
- 12 Skills program for awareness, connectedness, and empowerment: A conceptual framework of a skills group for individuals with a psychosis-risk syndrome. 14, ○
- 11 Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. **2023**, 254, 178-189 ○
- 10 Auswirkungen von Lithium, Valproat, Carbamazepin und Antipsychotika auf die Kognition bei bipolarer Stimmung. Ein systematisches Review. ○
- 9 Oxidative Stress Biomarkers among Schizophrenia Inpatients. **2023**, 13, 490 ○
- 8 Identification of Homogeneous Subgroups from Resting-State fMRI Data. **2023**, 23, 3264 ○
- 7 The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial. ○
- 6 Cognitive function in recovered COVID-19 Lebanese patients with schizophrenia. **2023**, 22, ○
- 5 Cross-diagnostic determinants of cognitive functioning: the muscarinic cholinergic receptor as a model system. **2023**, 13, ○
- 4 Comparisons of 25 cerebrospinal fluid cytokines in a case-control study of 106 patients with recent-onset depression and 106 individually matched healthy subjects. **2023**, 20, ○
- 3 Probing the Association between Cognition, Suicidal Behavior and Tryptophan Metabolism in a Sample of Individuals Living with Bipolar Disorder: A Secondary Analysis. **2023**, 13, 693 ○

2 Automatic evaluation-feedback system for automated social skills training. **2023**, 13, ○

1 Resting state hyperconnectivity of the default mode network in schizophrenia and clinical high-risk state for psychosis. ○